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Summary 
 
 
Myocardial infarction (MI) is a leading cause of death worldwide. Timely restoration 
of coronary blood flow to ischemic myocardium significantly reduces acute infarct 
mortality and attenuates ventricular remodeling. However, surviving MI patients 
frequently develop heart failure, which is associated with reduced quality of life, high 
mortality rate (10% annually), as well as high healthcare expenditures. The main 
processes involved in the evolution of heart failure post-MI are the great loss of 
contractile cardiomyocytes during ischemia-reperfusion and the subsequent complex 
structural and functional alterations, which are rooted in modifications at molecular 
and cellular levels in both the infarcted and non-infarcted myocardium. However, we 
still lack efficient treatments to prevent the development and progression of left 
ventricular remodeling. The improved survival rate of acute MI patients combined 
with the lack of effective therapy for post-MI remodeling contributes to the high 
prevalence of heart failure. 
 
Cardiac Magnetic Resonance Imaging (MRI) is an important tool for diagnosis and 
assessment of MI. With the advancement of this technology, the frontier of MRI has 
been extended to probing molecular and cellular events in vivo and non-invasively. In 
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combination with assessment of morphology and function, the visualization of 
essential molecular and cellular markers in vivo could provide comprehensive, 
multifaceted views of the healing process in infarcted hearts, which might give new 
insight for the treatment of acute MI. In this thesis, molecular and cellular cardiac 
MRI methods were established to visualize and investigate inflammation and calcium 
flux in the healing process of acute MI in vivo, in a clinically relevant rat model. 
 
Healing of MI is a delicately orchestrated inflammatory process, in which monocytes 
are central effectors and regulators. In Chapter 3 of the thesis, fluorine-19 (19F) MRI 
was utilized to unambiguously visualize the spatiotemporal distribution of monocytes 
and their descendant macrophages in reperfused MI complicated by microvascular 
obstruction (MVO) and intramyocardial hemorrhage (IMH), two strong indicators of 
poor prognosis. As in previous studies, we found that IMH and MVO were closely 
associated.  However, they differ with respect to innate immune responses. While 
monocyte recruitment was observed proportional to the severity of ischemia-
reperfusion injury when MVO was absent, a distinct mismatch was observed between 
the severity of the ischemia-reperfusion injury and monocyte recruitment in the MVO 
region. This result is surprising because monocyte infiltration is expected to be high 
in the severely damaged MVO; we observed that few monocytes were recruited to 
this region. Four weeks after MI of similar initial size, MVO hearts in comparison to 
those with only IMH, demonstrated significantly reduced recovery of ejection 
fraction, which was associated with more intense  replacement fibrosis consisting of 
significantly less thick collagen fibers. The above findings support that MVO is a 
stronger predictor of worse functional prognosis after acute MI. However, the 
relationship between the increased post-MI fibrosis and the monocyte infiltration 
pattern of MVO hearts needs further investigation. The monocyte recruitment might 
present a potential diagnostic and therapeutic target that could be longitudinally 
monitored by the combination of 19F-MRI and proton MRI. 
 
During the healing process of MI, remodeling also takes place in structure and 
function of non-infarcted myocardium. As one of the most important ions in the ion 
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signal system of the heart, calcium signaling has been found to be altered in acute and 
chronic MI hearts. We improved and applied the quantitative manganese enhanced 
MRI (MEMRI) method in both sub-acute and chronic MI rats, to probe the influx and 
efflux of calcium in infarcted and non-infarcted myocardium in vivo. In addition, 
fundamental questions concerning the relationship between manganese ion infusion 
rate, its cumulative dose, and the enhancement of the spin-lattice relaxation rate 
constant (R1) in blood, myocardium and other tissues were addressed. We were able 
to reveal the R1 dynamics of infarcted and non-infarcted myocardium in vivo with 
high spatiotemporal resolution. Interestingly, significantly reduced R1 enhancement 
was observed in various tissues in sub-acute MI rats, in comparison to both control 
and chronic MI rats. This phenomenon seems largely, if not entirely, due to the 
significantly reduced manganese ion concentration in arterial blood in sub-acute MI 
rats. Moreover, we discovered that intravenous infusion rates of manganese 
significantly influence the change of R1 in blood and thus that of R1 in myocardium, 
given the same total infusion dose. These findings highlight the importance of 
relating R1 enhancement in myocardium to the changes of R1 in blood and the 
myocardial arterial perfusion, when interpreting quantitative MEMRI as a surrogate 
of calcium activities in myocardium.  
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Zusammenfassung 
 
 
Myokardinfarkte (MI) sind eine der häufigsten Todesursachen weltweit. Eine 
rechtzeitige Wiederherstellung des koronaren Blutflusses im ischämischen Myokard 
reduziert signifikant die Sterblichkeitsrate akuter Infarkte und vermindert das 
ventrikuläre Remodeling. Überlebende MI-Patienten entwickeln jedoch häufig eine 
Herzinsuffizienz, die mit einer reduzierten Lebensqualität, hohen Sterblichkeitsrate 
(10% jährlich), sowie hohen Kosten für das Gesundheitssystem einhergeht.  
Die Entwicklung der Herzinsuffizienz nach einem MI ist auf den hohen Verlust 
kontraktiler Kardiomyozyten, während der Ischämie-Reperfusion zurückzuführen. 
Anschließende komplexe strukturelle und funktionelle Veränderungen resultieren aus 
Modifikationen des infarzierten und nicht infarzierten Myokards auf molekularer und 
zellulärer Ebene. Die verbesserte Überlebensrate von Patienten mit akutem MI und 
das Fehlen effizienter Therapien, die die Entwicklung und das Fortschreiten des 
ventrikulären Remodelings verhindern, führen zu einer hohen Prävalenz der 
Herzinsuffizienz. 
Die kardiale Magnetresonanztomographie (MRT) ist eine wichtige Methode zur 
Diagnose und Beurteilung des Myokardinfarktes. Mit dem technologischen 
V 
 
Fortschritt wurden die Grenzen der MRT erweitert, so dass es heute möglich ist, auch 
molekulare und zelluläre Ereignisse in vivo und nicht-invasiv zu untersuchen. In 
Kombination mit kardialer Morphologie und Funktion könnte die Visualisierung 
essentieller molekularer und zellulärer Marker in vivo weitreichende Einblicke in den 
Heilungsprozess infarzierter Herzen liefern, was zu neuen Erkenntnissen für ein 
besseres Verständnis und bessere Therapien des akuten MI führen könnte. 
In dieser Arbeit wurden Methoden für die molekulare und zelluläre kardiale MRT-
Bildgebung der Inflammation und des Kalziumstroms im Heilungsprozess des akuten 
Myokardinfarktes in vivo in einem Rattenmodel mit klinischer Relevanz etabliert. 
Die Heilung des MI ist ein feinabgestimmter inflammatorischer Prozess, in dem 
Monozyten zentrale Effektoren und Regulatoren sind.  
In Kapitel 3 dieser Arbeit verwendeten wir Fluor-19 (19F)-MRT für die eindeutige 
Visualisierung der räumlichen und zeitlichen Verteilung von Monozyten und den aus 
ihnen hervorgehenden Makrophagen im reperfundierten MI, die durch 
mikrovaskuläre Obstruktion (MVO) und intramyokardiale Hämorrhagie (IMH), zwei 
starke Indikatoren für eine schlechte Prognose, gekennzeichnet sind. Es zeigte sich, 
dass IMH und MVO eng assoziiert sind, sich aber hinsichtlich der Antwort des 
angeborenen Immunsystems unterscheiden: in Regionen in denen keine MVO vorlag, 
war die Rekrutierung von Monozyten proportional zur Schwere des  
Reperfusionsschadens. In Regionen mit  MVO zeigte sich jedoch eine eindeutige 
Diskrepanz zwischen der Schwere des Reperfusionsschadens und der hochgradigen 
Einschränkung der Monozyten-Rekrutierung. Vier Wochen nach einem MI ähnlicher 
anfänglicher Größe zeigten MVO-Herzen im Vergleich zu solchen mit nur 
intramyokardialer Hämorrhagie eine signifikant reduzierte Erholung der 
Ejektionsfraktion. Verglichen mit IMH-Herzen, hatten die MVO-Herzen deutlich 
mehr narbige Fibrose, welche aus signifikant weniger dicke Kollagenfasern besteht. 
Diese Ergebnisse unterstützen die These, dass die MVO nach einem akuten MI ein 
stärkerer Prädiktor einer schlechteren funktionellen Prognose ist.  
Der Zusammenhang zwischen der erhöhten Postinfarkt-Fibrose und dem Monozyten-
Infiltrationsmuster von MVO-Herzen bedarf jedoch weiterer Untersuchungen. Die 
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Monozyten-Rekrutierung könnte ein potentielles diagnostisches und therapeutisches 
Ziel darstellen, das über einen längeren Zeitraum mittels  kombiniertem 19F- und  
Protonen-MRT überwacht werden könnte. 
Während des Heilungsprozesses nach einem MI findet auch ein Remodeling der 
Struktur und Funktion von nicht infarziertem Myokard statt. In akuten und 
chronischen MI-Herzen zeigen sich Veränderungen im Kalzium-Signalweg, dem 
wahrscheinlich wichtigsten Ionen-Signalsystem des Herzen. Wir optimierten eine 
Methode zur manganverstärkten MRT und nutzten sie in subakuten und chronischen 
MI-Ratten, um den Ein- und Ausstrom des Kalziums im infarzierten und nicht 
infarzierten Myokard in vivo zu untersuchen. 
Im Weiteren befasst sich die Arbeit mit fundamentalen Fragen bezüglich des 
Zusammenspiels zwischen der Infusionsrate der Manganionen, deren kumulativer 
Dosis sowie der Erhöhung der Spin-Gitter Relaxationskonstante (R1) im Blut, 
Myokard und anderen Geweben. Wir konnten die R1-Dynamik des infarzierten und 
nicht infarzierten Myokards in vivo mit einer hohen räumlichen und zeitlichen 
Auflösung darstellen. Interessanterweise konnte, in sub-akuten MI-Ratten, im 
Vergleich zu Kontroll- und chronischen MI-Ratten, eine signifikant reduzierte R1-
Erhöhung in verschiedenen Geweben beobachtet werden. Diesem Phänomen scheint 
zum größten Teil, wenn nicht gänzlich, eine signifikant reduzierte 
Manganionenkonzentration im arteriellen Blut von sub-akuten MI-Ratten zugrunde 
zu liegen. Darüber hinaus haben wir gesehen, dass bei gleicher Infusionsdosis, die 
intravenöse Infusionsrate von Mangan einen signifikanten Einfluss auf die 
Veränderung des R1 des Blutes und somit auch des R1 im Myokard hat. Diese 
Ergebnisse unterstreichen, dass es wichtig ist, die R1-Anreicherung im Myokard auf 
die R1-Veränderungen im Blut und auf die arterielle Myokardperfusion zu beziehen, 
wenn man die quantitative manganverstärkte MRT als Surrogat der Kalziumaktivität 
im Myokard interpretiert. 
 
  
 
 
Chapter 1 
 
Basics of Myocardial Ischemic Injury 
and Heart Failure 
 
Myocardial infarction (MI) is a leading cause of death worldwide. Timely 
restoration of coronary blood flow to ischemic myocardium significantly reduces 
acute infarct mortality and attenuates ventricular remodeling. However, surviving 
MI patients frequently develop heart failure, which is associated with reduced 
quality of life, high mortality rate (10% annually), as well as high healthcare 
expenditures. The main processes involved in the evolution of post-MI heart 
failure are the great loss of contractile cardiomyocytes during ischemia-
reperfusion and the subsequent complex structural and functional alterations, 
which are rooted in modifications at molecular and cellular levels in both the 
infarcted and non-infarcted myocardium. Unfortunately, we still lack efficient 
treatments to prevent the development and progression of left ventricular 
remodeling. The improved survival rate of acute MI patients combined with the 
lack of effective therapy for post-MI remodeling contributes to the high 
prevalence of heart failure1. In this chapter, the physiology, pathophysiology and 
clinical aspects of myocardial infarction and heart failure are briefly reviewed. 
 
 
 
 
1.1   Myocardium 
 
The heart functions as a pump to supply blood to both pulmonary and systematic 
circulation. It is comprised of three types of cardiac muscles: atrial muscle, 
ventricular muscle and specialized excitatory and conductive muscle fibers. The 
former two are the force sources of the pump function and the later one is featured 
by its automatic rhythmical electrical discharge capabilities, which can form or 
conduct action potentials. These muscle cells are connected by intercalated discs 
in parallel bundles and further arranged in helical sheets to compose two 
functional syncytiums: the atrial syncytium and the ventricular syncytium. The 
normal rhythmical impulse is generated in sinus node locating in right atrial wall 
and is delayed in atrioventricular (A-V) node before propagating to ventricles 
along A-V bundle, left and right bundles and finally to all parts of the ventricles 
via Purkinje fibers. The conduction delay in A-V node permits the atria to contract 
shortly ahead of ventricles, which is critical for pumping blood efficiently2. 
 
The primary function of cardiomyocytes is to contract. The excitation-contraction 
coupling is the fundamental physiological process to convert electrical stimulus to 
mechanical response in cardiac myocytes. The depolarization of the resting 
membrane potential of myocayte initiates this process by allowing a small amount 
of calcium ions (Ca2+) entering the cell via long-lasting (L-type) calcium channels. 
This small amount of Ca2+ triggers the terminal cisternae to open the calcium-
release channels and release a large amount of Ca2+, which eventually results in 
100-times increase of intracellular Ca2+ in concentration. The free calcium ions 
bind to Troponin-C (TN-C), induce the conformational change of troponin-
tropomyosin complex that exposes a myosin binding site on actin, and result in 
adenosine triphosphate (ATP) hydrolysis and movement of actin relative to 
myosin. The actin and myosin filaments sliced past each other, so that the 
sarcomere length shortens, thereby myocardium contracts. As to the end of action 
potential, the calcium influx diminishes and the intracellular Ca2+ is pumped into 
sarcoplasmic reticulum (SR) actively by sarco-endoplasmic reticulum calcium 
ATPase (SERCA). The decreasing intracellular calcium concentration result in the 
removal of Ca2+ from TN-C, so that the change in conformation of troponin-
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tropomyosin complex and inhibition of actin-myosin binding, which allows the 
sarcomere to relax and restore its initial length2-5. 
 
The alterations of myocyte contractility by modulating calcium handling and 
myosin ATPase activity are classified as inotropy. The major mechanisms to alter 
inotropy are to regulate calcium entry into myocyte cytoplasm through L-type 
calcium channels and sarcoplasmic reticulum, the affinity of TN-C for calcium, 
myosin ATPase activity, and the re-sequester of calcium from cytoplasm by 
sarcoplasmic reticulum uptake and the efflux of calcium from myocyte.  The rate 
of myocyte relaxation is termed lusitropy, which results from the rate of calcium 
removal from cytoplasm after its release by the sarcoplasmic reticulum2, 4.  
 
To organize the force generating muscle cells structurally and functionally in the 
heart, a complex extracellular matrix (ECM) consisting of a complex mixture of 
collagen fibrils, elastin, cells, large molecules, growth factors, cytokines, and 
extracellular proteases etc. is interspersed between cardiomyocytes. Besides 
connecting myocytes and aligning contractile elements, EMC prevents 
overextending and disruption of myocytes. In addition, it transmits force and 
generates tensile strength to avoid rupture. It is a dynamic entity that evolves and 
remodels in response to pathophysiology. For instance, myocardial hypertrophy, 
ischemic cardiomyopathy and chronic myocarditis are accompanied by excessive 
collagen deposition in EMC, which contributes to impaired heart function. EMC 
is also critical in mediating angiogenesis by the rich soluble and insoluble 
angiogenic molecules, as well as the essential receptor signaling pathways in 
regulating endothelial cells migration, infiltration, proliferation, survival and 
architectural organization to finally establish vascular morphogenesis6-10. 
 
1.2    Ischemia-reperfusion Injury 
 
1.2.1 Ischemic Injury of Myocardium 
The heart demands large amount of oxygen and metabolites to generate adequate 
ATP aerobically for the repetitive contraction and relaxation.  At rest, the 
coronary arteries and its branches supply 5% of cardiac output to this organ, 
which counts for 0.4% of body weight. Under normal aerobic conditions, fatty 
acids supplies 60-90% metabolism for cardiomyotyes to produce ATP; and 
pyruvate from glycolysis and lactate oxidation constitutes to the rest needs. 
However, it has also been revealed that cardiac myocytes are very versatile in 
using substrates for aerobic metabolism. The weighting of carbohydrates, lactate, 
amino acids and ketones, rather than fatty acids, to supply energy for generating 
ATP could be dramatically increased when they are abundantly available in blood. 
Because cardiac myocytes extract 70-80% oxygen from hemoglobin, the oxygen 
extraction reserve is very limited. Therefore, an increased demand of oxygen and 
metabolic substrates due to increased contraction or heart rate is mostly delivered 
by increased coronary blood supply11. When coronary blood flow is interrupted 
completely (acute myocardial infarction), hypoxia swiftly shifts aerobic 
metabolism to anaerobic glycolysis, spontaneously with the decline and 
eventually the loss of myocyte contraction. Because the very limited substrate 
supplies for anaerobic glycolysis in ischemic myocardium and poor reserve of 
high-energy phosphate (HEP) in cardiac myocytes, ATP is quickly exhausted in 
ischemic zone. The lack of ATP results in sodium ions (Na+) and chloride ions 
(Cl-) retention and cell swelling by inhibiting sodium ion/potassium ion (K+)-
ATPase (Na+/K+-ATPase). The accumulation of acidic anaerobic metabolic 
products rapidly leads to the decline of intracellular pH. In addition, the 
intracellular osmotic load increases due to the boost of lactate and inorganic 
phosphate etc., and myocytes become edematous. The intracellular Ca2+ is 
believed to increase slightly in the late reversible phase12. In humans and large 
animals, an episode of 20 minutes (min) ischemia followed by reperfusion does 
not induce necrosis in myocardium. The prolonged ischemia before restoration of 
coronary circulation can cause partly (20minutes - 3 hours) to completely (3-6 
hours) transmural necrosis in the involved ventricular walls13-17.  
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1.2.2 Reperfusion Injury 
In the past two decades, a series of systematic data from both experimental 
models and clinics convincingly showed that the timely restoration of blood 
supply to MI regions reduces MI size and improves the healing process, so that 
the improved clinical out-comes18. However, to reperfuse the infarcted 
myocardium seems unavoidably induce injuries16. The cardiac dysfunctions 
caused by reperfusion injuries are classified into four types: 1) myocardial 
stunning, which refers to the “mechanical dysfunction that persists after 
reperfusion despite the absence of irreversible damage and despite the restoration 
of normal or near-normal coronary flow”19; 2) microvascular obstruction (MVO), 
referring to the hypoperfused myocardial tissue despite the patent epicardial 
coronary vessel, due to functional or anatomical changes of coronary 
microcirculation20; 3) reperfusion arrhythmias; and 4) lethal reperfusion injury, 
referring to “myocardial injury caused by the restoration of coronary blood flow 
after an ischemic episode”16.  
 
The mechanisms of reperfusion injury have been investigated intensively in the 
past three decades. The following mediators have been found critical in the 
induction of reperfusion injury: 1) Reactive oxygen species (ROS). They are 
molecules with unpaired electrons in their outer orbit and are able to neutralize 
nitric oxide, damage myocytes and endotheliums directly and trigger 
inflammation. Stunned myocardium is thought to be injured mainly by oxidative 
stress. 2) Intracellular calcium overloading. Sarcolemmal membrane loses normal 
function of regulating calcium gradient crossing membrane due to ischemic 
injury. Moreover, sarcoplasmic reticulum is damaged by oxidative free radicals 
during reperfusion. Consequently, the Ca2+ concentration increased dramatically 
in cytoplasm and mitochondria, which in turn results in cell death. 3) 
Inflammation. The most recent evidence demonstrated that inflammasomes, the 
crucial signal to initiate inflammatory reaction after ischemia-reperfusion, was 
formed in cardiac fibroblasts rather than in cardiomyocytes. Their activation 
resulted in interleukin-1 production, which triggered the downstream 
inflammatory reactions in the heart21. These inflammatory signals in MI activate 
and facilitate neutrophils to attach to and transmigrate damaged microvasculature. 
They produce large amount of free radicals and degradative enzymes that induce 
cell death and amplify inflammation. Neutrophil depletion in animal models of 
reperfused MI suggests that neutrophils might induce significant injuries to 
myocardium. The plugging of neutrophils is believed to be an important cause of 
MVO, a severe dysfunction of microvasculature in infarcted myocardium and a 
strong indicator of adverse left ventricular (LV) remodeling22, 23. Furthermore, pH 
value and metabolic modulation etc. were found to influence myocardial injury 
upon reperfusion after ischemia16.  
 
 
1.3    Inflammatory Response in Myocardial Infarction 
 
Both reperfused and non-reperfused acute myocardial infarctions are associated 
with inflammatory response, which starts on-site shortly after the initiation of 
ischemia and lasts for weeks until the scar formation is finished24. In patients with 
chronic MI, systemic inflammatory markers have been found elevated, which is 
believed to contribute significantly to the development of heart failure25.  
 
The release of sub-cellular membrane components by MI activates complement 
system, induces the generation of ROS and triggers the activation of a series of 
cytokines and expressions of adhesion molecules, among which Tumor Necrosis 
Factor (TNF)-α, Interleukin (IL)-8 and Complement (C) 5a were found essential 
in regulating neutrophil recruitment after reperfusion. After activation, neutrophils 
marginate in blood stream, roll along capillary wall, attach to endotheliums and 
eventually transmigrate into injured myocardium. Cytotoxic effects can be 
induced by direct adherence of neutrophil to cardiac myocytes via Intercellular 
Adhesion Molecule (ICAM)-1 or by proteolytic enzymes and free radicals 
produced by neutrophils24.  
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1.4    Healing of Injuries in Myocardium 
 
Even though inflammation appears to be mostly detrimental during ischemia and 
shortly after reperfusion, it is necessary for the healing of myocardial injury. Mast 
cells and blood monocytes that are recruited to MI have been found essential in 
regulating and coordinating the healing process through modulating a series of 
cytokines, growth factors and other elements in inflammatory signaling26, 27. 
There are also data from both clinical and experimental settings suggesting that 
the enhanced inflammation after reperfusion therapy was beneficial for more 
effective healing28, 29. 
 
Blood monocytes are the key player in the healing of MI. They are recruited to MI 
by chemokines and their cognate receptors, among which Transforming Growth 
Factor (TGF)-β1 and Monocyte Chemoattractant Protein (MCP)-1 were found 
most important. The roles of monocytes and their descendent macrophages in MI 
healing were not elucidated until recent years, in part due to the heterogeneity and 
divergent functions of monocytes, as well as their unclear fate after releasing from 
bone marrow. Recently, researchers and clinicians become more aware that blood 
monocytes are a mixture of at least two but likely more than two subsets of 
mononuclear cells that share similar morphology but differ profoundly in 
functions. The two subsets of blood monocytes, inflammatory (or classical) and 
reparative monocytes, came into light in the past years. The corresponding cell 
populations have been identified in small rodents like mice, large animals like 
swine and in humans30, 31. The classical markers of the inflammatory monocytes 
are Ly-6Chi (Gr1hi CCR2+ CX3 CR1lo) in mice and CD14+ CD16- in humans. 
After effectively infiltrating sites of inflammation, they are potent in 
phagocytosis, proteolysis, and inflammatory functions. The reparative monocytes, 
counterpart of inflammatory monocytes, are identified by Ly-6C lo (Gr1lo CCR2− 
CX3CR1hi) in mice and CD14+ CD16+ in humans. They are less virtuous in 
inflammatory functions but promoting angiogenesis, myofibroblasts proliferation 
and collagen deposition to heal the injured tissue with scar formation30, 31. 
Nahrendorf et al. revealed in a mouse MI model that these two subsets of blood 
monocytes were recruited to non-reperfused MI in a biphasic fashion: the Ly-6C hi 
monocytes infiltrated MI mainly during the first phase (from Day 1-3 after MI) to 
break down necrosis and clear debris. In the second phase (from Day 4-7 after 
MI), the Ly-6Clo monocytes prevailed, resulting in effective tissue repair32. These 
findings provide crucial mechanistic explanations in experimental MI for the 
seemly contradictory functions of the two subsets of monocytes but well-
orchestrated recruitments and function for efficient MI healing32. Importantly, a 
similar recruitment pattern of the corresponding monocyte subsets were also 
found in acute MI patients with reperfusion therapy, even though the analysis was 
based on peripheral blood samples, rather than the direct examinations of 
monocytes in MI tissue33. 
 
Interleukin-10 (IL-10) and mast cells have been found important in modulating 
the inflammatory responses after MI. Known as a cytokine mainly produced by 
activated Th2 cells and endotoxin-stimulated monocytes, IL-10 is potent in 
inducing functional, morphological and phenotypical changes on monocytes and 
macrophages. It seems suppress inflammation by prohibiting activated monocytes 
to produce pro-inflammatory factors like IL-1α, IL-1β, TNF-α, IL-6, 8 and 1234, 35. 
In early stage after MI, mast cells degranulate to produce preformed histamine 
and TNF-α. In later phase of healing, they seem to be very important in 
coordinating healing by orchestrating cell-cell interaction, cytokines, growth 
factors and extracellular matrix proteins. Together with monocytes and 
macrophages, mast cells induce fibroblast proliferation and angiogenesis by 
providing an environment of cytokines and growth factors. However, the 
mechanism of mast cell accumulation in MI is still unclear26.  
 
In healing process, fibroblasts are critical in secreting extracellular matrix 
constituents to form the necessary supporting system allowing cell growth, 
angiogenesis and therefore nutrients delivery and cell metabolism. In MI, 
fibroblasts were found to develop ultrastructural and phenotypic features of 
smooth muscle cells. They are called myofibroblasts. They proliferate after being 
recruited to MI zone by a series of cytokines and growth factors secreted from 
monocytes and macrophages, mast cells, and lymphocytes36. This inflammatory 
environment also activates proteinases, which result in dramatic remodeling of the 
extracellular matrix of myocardium. The activation of proteinases such as 
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urokinase-type plasminogen activator (uPA) and matrix metalloproteinase (MMP) 
have been found significant in this process35. The depletion of the activation of 
these proteinases was shown to attenuate adverse LV remodeling in mice37. 
 
 
1.5    LV Remodeling and Heart Failure 
 
A key characteristic of myocardial tissue is the low regenerative capacity. Most 
myocardial cells are terminally differentiated soon after birth. Although 
discoveries in the past decade have demonstrated that adult cardiomyocytes can 
proliferate38, 39 and there is a pool of resident cardiac progenitor cells, which can 
give rise to cardiomyocytes, endothelial cells and smooth muscle cells in vitro and 
in vivo, unfortunately they are insufficient for replacing the acute loss of a large 
number of myocardial cells. Rather, they seem to only participate in the continual 
replacement of apoptotic cardiomyocytes at a low basal level40, 41. As a 
consequence, the amount of contractile cells lost, or the infarct size, is a crucial 
determinant of adverse LV remodeling. The loss of 1g of myocardium represents 
approximately 20 million cardiomyocytes. 25% infarction of left ventricle causes 
heart failure41.  
 
Ventricular remodeling is central in the pathophysiology of heart failure 
development. In the early stage after MI, thinning and regional dilatation occurs in 
both infarcted and non-infarcted segments, resulting from slippage between 
muscle bundles and therefore the reduced number of cardiomyocytes distributed 
across the MI region42-44. Accompanied by a shift of cavity configuration from 
elliptical to more spherical, the enlarged LV chamber tends to maintain the 
cardiac output by increasing stroke volume. In later stage, myocardial hypertrophy 
becomes the predominant factor to compensate the heart performance, as LV 
chamber enlargement advances together with increasing cardiomyocyte apoptosis 
and interstitial fibrosis. Eventually comes the decompompensation phase, when 
the augmentation of heart function is insufficient and the cardiac output declines 
progressively in spite of the geometrical and histological changes of the heart45. 
The progressive LV remodeling and development of heart failure are also 
associated with up-regulation of numerous humoral factors, for example the 
rennin-angiotensin-aldosterone axis and the adrenergic nervous system and pro-
inflammatory cytokines etc. 
 
 
1.6    Clinical Needs 
 
In the last three decades, a substantial decrease in early and late mortality in acute 
myocardial infarct patients has been achieved mainly due to the wide acceptance 
of the open-vessel theory46, emphasizing the need of early reperfusion of the 
infarct-related artery by means of percutaneous coronary intervention (PCI), 
intravenous thrombolytic therapy, or coronary artery bypass graft (CABG) 
surgery. Secondly, it is contributed by the availability of supportive medication 
adequately controlling life-threatening arrhythmias, preventing thrombo-embolic 
events, and reducing LV remodeling e.g. angiotensin-converting enzyme 
inhibition. Thirdly, cardiac revalidation and secondary prevention programs 
further reduce mortality47. Nevertheless, large multi-center studies have shown 
despite early and successful reperfusion and optimized medication, the actual 
hospital mortality remains approximately 7%48. Moreover, a sizable number of 
surviving MI patients develops toward ischemic dilated cardiomyopathy and heart 
failure, with permanently reduced quality of life. The survival and Ventricular 
Enlargement (SAVE) trial indicated that the long-term mortality of acute MI 
patients was still as high as 20% after 3.5 years, with treatment of angiotensin-
converting-enzyme (ACE) inhibitor to reduce LV remodeling and progression of 
heart failure49. Therefore, on one hand more acute MI patients survived due to the 
effective acute treatment; on the other hand, currently available therapies are 
insufficient to treat those survivors chronically. This situation results in the 
increased number of heart failure patients. There is need to understand and treat 
heart failure better. 
 
  
 
 
Chapter 2 
 
Basics of Molecular and Cellular 
Cardiac Magnetic Resonance Imaging of 
Myocardial Infarction 
 
According to the consensus of the American college of Cardiology (ACC) and 
European Society of Cardiology (ESC), myocardial infarction is diagnosed 
fundamentally by cardiac enzymes such as troponin I and T as well as creatine 
kinase-MB, and electrocardiography (ECG)50. However, cardiac enzymes are 
restrained by insensitivity in sub-acute MI, a lack of information on MI location 
and moderate association to MI size. In addition, ECG has limited sensitivity in 
MI absent of Q-wave and sometimes poor specificity in the setting of other 
cardiopulmonary abnormalities. 
 
Medical imaging is valuable in assisting diagnosis, characterizing severity, 
guiding therapy, monitoring functional recovery and predicting long-term 
outcomes51-54 of MI. Magnetic Resonance Imaging (MRI) has a relatively high 
spatiotemporal resolution and versatile tissue contrast. With increasing 
accessibility, cardiac MRI is becoming an important tool for diagnosis and 
assessment of MI in clinical routine, trials and research52. Cine MRI has been 
recognized as the golden standard to evaluate global contractile function of the 
heart50. Regional contractility can also be rendered by cine MRI or other MR 
techniques. Combined to MR contrast media, cardiac MRI is the preferred method 
to delineate MI and characterize microvascular function after ischemic insults50, 52. 
With the advancement of this technology, the frontier of MRI has been extended 
to probing molecular and cellular events in vivo and non-invasively55. In 
combination with the assessment of morphology and function, the visualization of 
essential molecular and cellular markers in vivo could provide comprehensive, 
multifaceted views of the healing process in infarcted hearts, which might provide 
new insights for the treatment of acute MI. Even though molecular and cellular 
MRI is mostly demonstrated in experimental animals, tremendous potential 
impact might be brought to clinical practice when molecular and cellular MRI is 
integrated to conventional cardiac MRI56, 57. 
 
In this thesis, molecular and cellular cardiac MRI methods were established to 
visualize and investigate inflammation and calcium flux in the healing process of 
acute MI in vivo, in a clinically relevant rat model. 
 
2.1   Basics of Magnetic Resonance Physics 
 
MRI is based on recording and analyzing radio signals emitted from nuclei in 
response to external magnetic fields58. The phenomenon of Nuclear Magnetic 
Resonance (NMR) was discovered by Bloch59 and Purcell60 independently in 
1946. The rotation of a nucleus around its own axis is regarded as a spin, whose 
magnetic moment is of vectorial quantity. Quantum mechanics predicts that only a 
certain limited number of projections of a spin on a given axis are allowed. A 
resonance is induced when spins reach coherent frequency and phase, resulting in 
enhanced amplitude of magnetism. Conventionally, MRI exploit proton (1H) to 
image anatomical and functional features of living bodies, due to the high natural 
abundance and large magnetic moment of proton. 
 
At the absence of a static external magnetic field (B0), the orientations of nuclear 
magnetic moments are random, which results in zero magnetization in the bulk 
tissue. However, in exposure to an external magnetic field, spins of nuclei 
allineate to B0 gradually by circular movements, which is termed ‘Larmor 
precession’. The magnetic moment of the precessing nucleus (M) is expressed by 
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a vector, which can be decomposed into the transverse (Mxy) and longitudinal 
(Mz) magnetization vectors. The Larmor frequency ωL describes the frequency of 
precession of M around B0. It is determined by the strength of the static external 
magnetic field B0 in unit of teslar (T) and the gyromagnetic ratio γ in unit of 
megahertz per teslar (MHz/T).  
ωL = γ B0 
For proton hydrogen, γ = 42.576 MHz/T. 
 
In response to a static external magnetic field, the nucleus spins are either parallel 
or anti-parallel to B0, presenting the discrete low or high energy level respectively. 
Spins favor the low energy state over the high energy state; therefore, the parallel 
magnetic moments are slightly more numerous over the anti-parallel ones in bulk 
matter, resulting in a parallel net magnetization. In the transverse plane, the 
magnetization vectors are canceled out due to the random distribution in phase. 
However, only transverse magnetic vectors can be measured by MRI scanners. 
Therefore, a strategy is needed to manipulate the net magnetization to produce a 
transverse vector detectable by MRI machine. For this, pulse radiofrequency (RF) 
waves with the Larmor frequency is applied by an RF magnetic field 
perpendicular to B0. When a 90° RF pulse are applied, the longitudinal vector is 
flipped to the transverse plane and process coherently in phase, which emits a 
robust radiosignal of the Larmor frequency. When the RF pulse is interrupted, the 
spins start to lose phase coherence and return to equilibrium state. This is termed 
relaxation, which consists of two distinct and independent processes: the spin-
lattice relaxation and the spin-spin relaxation. The former describes spins 
returning from the high to low energy state. The spin-lattice relaxation time 
constant (T1) is the time for 63% recovery of the longitudinal magnetization (Mz). 
The spin-spin relaxation reflects the decay of transverse magnetization (Mxy) due 
to the dephasing of the spins. The spin-spin relaxation time constant (T2) is the 
time for the longitudinal magnetization (Mz) decreases to 37% of its maximum 
strength. 
 
The contrast of MRI is fundamentally based on the variation of T1, T2 and proton 
density (PD) in different tissues. By adapting parameters of the RF excitation and 
echo signal collection, MR images with different weightings of T1, T2 and PD 
components are produced.  Repetition time (TR) is the time interval between 
excitation pulses. When TR is long, more of the energy from the excitation pulse 
is to vanish due to spin-lattice relaxation; therefore, the image is less T1 weighted. 
Echo time (TE) is the time between the excitation pulse and the maximum of the 
echo signal. A long TE allows spins to lose phase coherence more sufficiently and 
thereby generates stronger signal from tissue with long T2. In addition, the 
inhomogeneity of magnetic field in approximate to spins can accelerate the 
dephasing of spins after turning off the excitation pulse, which is termed magnetic 
susceptibility or T2* effect. Relatively long TE permits apparent signal loss 
caused by inhomogeneity of local magnetic field on T2* weighted image (T2*WI). 
Worthy noted, T2* effect also shortens T2 of the local tissue. According to 
practical needs, different weighted images can be achieved by adjusting TR and 
TE, as well as modulating the schemes of MR sequences61. 
 
To image the heart with MRI, electrocardiography (ECG) and breath-hold are 
often needed to prevent image artifacts due to cardiac and respiratory motions. In 
small animals, breath control is often achieved by incubating the animal and 
ventilating by respiratory machines. Otherwise, a combination of respiratory and 
cardiac triggering system is needed instead. With the advance in acquisition and 
post-processing technologies, cardiac and respiratory motion artifacts can also be 
avoided by continuous signal acquisition but selective post-construction62. 
 
2.2   Conventional Cardiac MRI of Myocardial Infarction 
 
In known or suspected MI patients, cardiac MRI can provide comprehensive 
morphological and functional evaluations of the heart by the determination of MI  
location, size and transmurality, as well as critical information associated with 
microvascular pathophysiology, for instance edema, intramyocardial hemorrhage 
(IMH) and microvascular obstruction (MVO). Besides being a powerful imaging 
modality in diagnosis and assessment of MI, cardiac MR (CMR) has also been 
increasingly applied in clinical trials to measure surrogate end points for instance 
CMR derived infarct size and pump function52. 
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2.2.1 Global and Regional Ventricular Function 
Coronary artery occlusion initiates an immediate loss of contractility in the 
ischemic myocardium. The global ventricular function post MI is decided by the 
extent of myocardial necrosis, amount of stunned myocardium and impact on 
contractility in the remote, non-infarcted myocardium. Ventricular remodeling 
takes place over time after infarction, in which functional, morphological and 
geometrical changes of the heart are determined by numerous parameters 
including size, location and transmurality of infarct, MVO and area at risk etc. 
The magnitude of potential functional recovery needs to be measured in the order 
of a few percentages63, 64. Presently, Cine MRI is the favorable technique to 
evaluate ventricular volume and function fully quantitatively. With that, 
Significantly smaller samples could provide the same statistical power to assess 
ventricular remodeling65, 66.  
 
Systolic contraction of myocardium induces ventricular wall thickening, 
circumferential and longitudinal shortening, resulting in a complex three 
dimensional deformation of myocardial wall23, 67. The above contraction 
parameters are attenuated or abrogated by reversible or non-reversible local 
injuries of myocardium. Therefore, they can serve to describe or monitor regional 
contractile function. Alternatively, regional ventricular function can be evaluated 
by regional EF parameter, which describes the contribution of the infarct 
myocardium to the ejection of blood. All the above data on regional function can 
be extracted from the same Cine MRI data used for quantification of global 
volumes and function.  
 
2.2.2 Characteristics Determining Infarct Severity 
Infarct severity is mainly determined by infarct volume and infarct transmurality. 
In addition, infarct location and microvascular obstruction are also determinants 
of worse adverse LV remodeling and clinical outcomes: anterior MI was found 
associated with more LV remodeling and worse outcome, in comparison to non-
anterior MIs; the presence of MVO was correlated to early post-MI compilations, 
LV remodeling and poor recovery of heart function independent on MI size23, 68. 
Other parameters that might influence outcome are post-reperfusion 
intramyocardial hemorrhage and the ratio of infarct size to area-at-risk. IMH is 
found correlated to extensive adverse remodeling of LV, even though it is still a 
debate whether its prognostic value is independent of MI size and MVO69-72. The 
amount of viable myocardium (stunned myocardium) in the initial ischemic 
region can be estimated by the infarct to area-at-risk ratio73.  
 
Contrast enhanced (CE) MRI based on gadolinium contrast agent and inversion-
recovery (IR) gradient-echo MR sequence is the preferred technique to delineate, 
characterize and monitor myocardial infarcts in both acute and chronic settings74-
77. Infarct volume, transmurality, circumferential and longitudinal extents, and 
their changes over time can be excellently assessed. MVO is visible as a dark 
zone in the infarct core on the early CE MRI. Contrast agents could slowly fill in 
over time78 or MVO could persist even in late enhancement phase. Recent clinical 
data suggested that MVO on late enhancement phase had stronger prognostic 
value on worse clinical outcomes79, 80. An additional T2-weighted MRI provides 
estimation of the extent of edematous myocardium after ischemic insult. Edema 
appears hyperintense signal. The presence of intramyocardial hemorrhage in 
concomitant to edema appears as a central hypointense core surrounded by 
hyperintense rim73, 81, 82 on T2WI or signal voids on T2*WI.  
 
2.2.3 Infarct Expansion, Shrinkage and Remodeling  
As early as the first hours after ischemia, myocardial infarction, especially the 
large and transmural ones, undergoes infarct expansion due to the slippage 
between muscle bundles and therefore the reduced number of cardiac myocytes 
across the infarcted LV wall. Necrosis is phagocytized by macrophages and the 
preexisting extracellular matrix is digested by proteases. Progressively, wounded 
myocardium is replaced by granulation tissue, which contains a large number of 
fibroblasts and myofibroblasts producing new collagen fibers. In the weeks and 
months thereafter, the infarct remodels and matures into an anisotropic scar 
consisting of high density of type I collagen bundles. During this process, infarct 
shrinkage occurs due to the absorption of necrosis and the dramatic change of 
tissue composition in MI, which often lead to a volume loss of 30 to 60%83. 
Valuable information concerning MI expansion, shrinkage and remodeling, 
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rendered by infarct volume, infarct transmurality, infarct surface, circumferential 
and longitudinal infarct length, infarct radii of curvature in 
longitudinal/circumferential direction, can be obtained by CE-IR MRI in 
combination with cine MRI in follow-up studies. 
 
2.3 Molecular and Cellular Cardiac MRI 
 
Molecular imaging is to visualize, characterize and non-invasively measure 
biological processes at the molecular and cellular levels in humans and other 
living systems56. The past two decades have witnessed a dramatic development of 
this domain, with the ever advance of imaging hardware and software, contrast 
agent synthesis and new knowledge of specific biomarkers of pathophysiological 
processes. The conventional medical imaging modalities are nuclear imaging, 
ultrasound imaging, X-ray computer tomography (CT), MRI/magnetic resonance 
spectroscopy (MRS). In addition, the integrated multi-modality imaging systems 
like CT-PET, CT-SPECT and PET-MRI provide more convenient image 
registration, facilitate interpretation of multi-modality images, and improve in-
depth understanding of pathophysiological processes in a systematic manner. 
They have potential to significantly impact early and sensitive diagnosis, as well 
as individualized therapy. In addition, in vivo optical imaging approaches, 
including fluorescence and bioluminescence imaging, have demonstrated unique 
advantages of good molecular sensitivity and favorable chemistry for the 
development of molecular imaging agents56, 57. 
 
Molecular and cellular MRI detects molecular and cellular events with the 
advantages of being non-invasive, tomographic, non-ionizing and excellent soft 
tissue contrast, as well as high spatial and temporal resolutions. With contrast 
agents that can modulate MR signal by magnetically modifying the interaction of 
tissue water and the surrounding environment, either positive or negative 
enhancement could be achieved for visualization of molecular and cellular 
activities. In cardiovascular system, preclinical applications of molecular and 
cellular MRI have been demonstrated in calcium channel activity of cardiac 
myocytes, stem cell and immune cell tracking, detection of cardiac myocyte 
apoptosis, myeloperoxidase activity as well as imaging and monitoring of 
atherosclerosis. These molecular and cellular MRI methods have been applied to 
acute and chronic myocardial infarction, myocardial stunning, acute and chronic 
rejection of allograph heart transplantations, auto-immune myocarditis, as well as 
ApoE-/- mice etc. 
 
Of the above mentioned molecular and cellular MRI methods and their 
applications in various disease models, the fundamental techniques can be 
classified into the following three categories:  
 
1. MRI cell tracking. 
2. MR imaging of pathophysiological processes with targeted contrast agents.  
3. Calcium influx and efflux measurements by manganese enhanced MR imaging 
and R1 mapping. 
 
2.3.1 MRI Cell Tracking 
Medical imaging is largely based on tissue differences in contrast, enabling to 
identify anatomical structure, to differentiate healthy tissue from pathological 
ones, and visualize disease processes. In 1H-MRI, a significant difference of 
relaxation (T1, T2 or T2*) between the target cells and the hosting tissue is 
needed to create enough contrast between the two, in order to visualize the target 
cells. A variety of approaches have been proposed to generate MR contrast for 
cell tracking. Both paramagnetic (e.g. gadolinium chelates84-88, manganese 
chloride89) and superparamagnetic agents e.g. iron oxide agents have been linked 
or incorporated to target cells, in order to change T1 or T2/T2* values. Besides 
the above direct labeling methods by using external paramagnetic or 
superparamagnetic agents, reporter genes have been developed for MR cell 
tracking in preclinical setups. Typically, they were engineered into cells to 
produce markers for MR cell tracking90-93. At present, iron oxide particles varied 
in diameters are the predominant agents for MRI cell tracking, due to the bio-
compatibility, high sensitivity and readily available setups in clinical MRI 
scanners. However, this method suffers from non-specificity, difficulty in absolute 
quantification of cells and incapability of differentiating multiple cell populations. 
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Instead, fluorine-19 (19F) labeling for MR cell tracking is an attractive alternative, 
which overcomes some of the limitations of iron oxide particle labeling and has 
potential for clinical translation94.  
 
2.3.1.1 Cell labeling with iron oxide nano-particles 
Although there are a few papers reporting the utility of paramagnetic MR contrast 
agents, such as gadolinium (Gd) chelates84-88 and manganese chloride (MnCl2)89, 
for intracellular labeling, their use is hampered by the low sensitivity on T1 
weighted images, the requisite of a very high intracellular concentration to shorten 
T1 times of surrounding water molecules, and the concern of toxicity in free ion 
status. Iron oxide nanoparticles, a superparamagnetic agent, are dominant in MR 
cell tracing, because of its robust effect on MR relaxivity, biocompatibility and 
easy accessibility. Besides shortening T1 and T2 values at high concentration, 
these iron contents have remarkable T2* effects. The strong superparamagnetic 
nature of these iron oxide nanoparticles generates local field gradients, which 
enhance dephasing of surrounding spins and produce significant signal loss 
(signal voids) on T2* weighted images. By incorporating with iron oxide agents, 
cells of interest are visible as hypointense areas on T2/T2* weighted MRI95. After 
being transplanted, cells labeled by iron oxide nano-particles could be isolated 
from homing tissue by tissue digestion and magnetic cell sorting, which gives a 
means to quantify and future characterize labeled cells96. 
 
Iron oxide nano-particles are a family of superparamagnetic contrast agents, 
consisting of a ferrite (maghemite or magnetite) core and a polymeric coating. 
Based on their size, they are categorized as monocrystalline iron oxide 
nanoparticles (MION, 10-30 nm in diameter)97, ultra-small superparamagnetic 
iron oxide (USPIO, 10-40 nm in diameter)97, 98, superparamagnetic iron oxide 
(SPIO, 60-150 nm in diameter)99, 100 and mircometer-sized iron oxide particles 
(MPIO, around 1 to few micrometers in diameter)101. Among them Ferucarbotran 
(Resovist®) and Ferumoxides (Endorem® and Feridex®) were FDA approved 
clinical grade reagents for enhancing MRI detection of liver tumors102 and 
metastatic lymph nodes103. Unfortunately, they have been withdrawn from the 
market. Recent attempts have demonstrated the novel applications of USPIO in 
inflammatory diseases104, microcirculation permeability105, blood volume106 and 
MR angiography98.  
 
Direct labeling with (U)SPIO particles remains the most commonly used strategy 
for MRI cell trafficking in cardiovascular system. It is a relatively simple method, 
allowing for fast and sensitive detection. However, it bears some limitations and 
shortcomings. As mentioned above, any signal loss arising from other origins (e.g. 
noise, hemorrhagic myocardial infarcts, the heart-lung interface) may interfere 
with the detection of (U)SPIO labeled cells107. In particular, IMH is a frequent 
finding in MI patients after reperfusion therapies78, 108-110. It could interfere with 
the visualization of iron oxide labeled cells111. The paramagnetic and 
superparamagnetic properties of hemoglobin breakdown products (e.g. 
methemoglobin, ferritin, hemosiderin) can induce local field heterogeneity and 
create signal voids on T2*-weighted images. Such signal voids appear similarly to 
the signal loss caused by iron oxide nanoparticle labeled cells. Although seldom 
mentioned in previous studies112-114, caution should be taken when interpreting 
MRI cell tracking using iron oxide particle labeling, in experimental reperfused 
MI models. The presence of T2* effect in reperfused MI zone could be caused by 
IMH. This is a concern for clinical translation of iron oxide particle labeling, 
because the majority of acute MI patients receive reperfusion therapy in Europe 
and North America. Moreover, it should be emphasized that iron oxide particles 
do not provide direct information concerning cell survival, proliferation, 
differentiation and quantification. It is also impossible to differentiate two or more 
groups of cells which are all labeled by iron oxide agents. In addition, every 
subsequent cell division will halve the intracellular iron content and result in 
gradual reduction of the cell detection. Therefore, direct cellular labeling with iron 
oxide is probably suitable for short-term cell tracking e.g. to locate labeled cells 
within the heart. Since the labeling is non-specific, iron contents could be passed 
on to surrounding cells e.g. macrophages or simply distributed extra-cellularly, 
which could produce false positive signals. False negative results may occur, as a 
result of partial volume effects or when the amount of labeled cells is too low in 
one imaging voxel.  
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2.3.1.2 MR reporter genes 
Direct cell labeling has several advantages, such as ease of manipulation and 
potential for use in the clinical setting. However, it does not fulfill the demands of 
providing in-depth insight in cell survival, proliferation and differentiation. As 
mentioned above, iron contents or other labeling materials are diluted as cells 
divide. Moreover, the intracellular incorporated contrast agents may be removed 
by a variety of pathways and eventually unable to create enough contrast. 
Therefore, the direct approach may not be ideal for long-term cell labeling. 
Reporter gene imaging in combination with MRI or MRS seems more suitable for 
long-term cell labeling in the preclinical setting. Using a transgene approach e.g. 
replication-defective adenovirus, genes are incorporated into the cellular DNA. 
The products of the reporter genes (e.g. enzymes, surface markers, membrane 
receptors) are expressed only in viable labeled cells. They may potentially reflect 
the function and differentiation status in a quantitative fashion. Moreover, 
offspring cells can be traced, as long as the engineered reporter gene incorporated 
into chromosomes is not silent or blunt. The above advantages make transgenic 
labeling strategies highly valuable for answering questions concerning the long-
term fate of labeled cells. At present, MR reporter genes are still limited to pre-
clinical research, because of the restrictions of sufficient bio-safety profile.  
 
Earlier attempts to transfect enzyme (creatine kinase – arginine kinase) genes to 
host tissues showed that products of incorporated genes were detectable by 31P-
MRS in vivo. Unfortunately, the interference of background tissue signal 
restricted their application. In addition, MRS does not provide spatial distribution 
of the marker, which makes enzyme reporter gene MRS less favorable for cell 
trafficking. In hunting reporter genes for MRI, a breakthrough was the ferritin 
gene91, 92. Ferritin is a metalloprotein consisting of 24 subunits, both light and 
heavy chains, and can coat up to 4500 Fe3+ ions. Unlike SPIOs, ferritin is 
predominately anti-ferromagnetic, resulting in a T2/T2* shortening several orders 
smaller than that of SPIOs. Cohen et al. were able to create a construct of TET-
EGFP-HA-ferritin, in which tetracycline (TET) regulated tightly the expression of 
enhanced green fluorescent protein (EGFP) and influenza (HA) hemaglutinin-
tagged ferritin heavy chain. When TET was retrieved, dramatic increases of both 
spin-lattice (R1) and spin-spin (R2) relaxation rates were detected in transfected 
rat glioma cells91. Over-expression of ferritin heavy chain could result in 
redistribution of intracellular iron and increase of intracellular iron contents, 
probably by up-regulating the transferrin receptor expression91. Almost at the 
same time, Genove et al. reported their success of delivering ferritin transgenes 
with a replication-defective adenovirus vector. After stereotactical injection of the 
adenovirus containing the ferritin reporter gene in the striatum of mice, robust 
contrast was seen on T2 and T2* weighted images, from 5 days to at least 39 days 
after injection92. This technique has also been applied to label stem cells for MRI 
cell tracking in animal models of ischemic cardiomyopathy. Tannous et al. 
generated a novel reporter gene expressing a cell surface receptor allowing 
monitoring gene expression and cell targeting90. Metabolic biotinylation of cell 
surface receptors can be used for in vivo imaging. Linking multi-modality contrast 
agents to avidin, which has an affinity 103-106 higher than the antigen-antibody 
interaction, provides signal enhancement in fluorescent imaging, MRI, PET and 
SPECT90. Although initially designed for monitoring gene expression in gene 
therapy, reporter genes are potentially translatable for cell labeling. They are 
promising for long-term observations of cell distribution, proliferation and 
differentiation. 
 
2.3.1.3 19F-MRI for cell tracking: an attractive alternative 
19F-MRI may be highly attractive for cell trafficking. Owing to a high 
gyromagnetic ratio of 40.05MHz/T and a spin ½ nucleus, 19F has 0.83 NMR 
sensitivity relative to proton and is naturally abundant. The advantage of using 
19F-MRI over 1H-MRI is the lack of NMR signal of endogenous fluorine, with 
other words there is no background signal and 19F-labeled cells are shown as ‘hot 
spots’ against a dark background115, 116. Moreover, it has the potential to quantify 
the labeled cells in vivo, based on 19F-MR spectroscopy or calibrated MRI data115, 
117. Anatomical localization of labeled cells can be achieved by superposing 19F-
MRI on 1H-MRI. Because various perfluorocarbon (PFC) compounds with 
distinct profiles of MR spectrum are available for cell labeling, multiple cell 
populations could be detected and quantified by simultaneous or separated MR 
measurements115, 117. 19F-MRI might bring interesting biological insights beyond 
the location and quantification of target cells, due to the versatile contrast 
rendered by the reaction of PFC to surrounding biological and chemical 
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environments. For instance, 19F-MRI using perfluorocarbon has been applied to 
report the pO2 in tumor micro-environment118. This could be extended to provide 
information about the reaction and behavior of engrafted cells in homing tissue. 
PFC emulsions, originally developed for red blood cell substitute, should be well 
tolerated (a maximal safe dose of 3ml/kg administrated intravenously in human 
beings)119.  
 
The first report on in vivo 19F-MRI cell tracking was as early as in 1997 by Noth 
et al120. In this serial in vivo study, macrophage tracking by 19F-MRI was 
demonstrated in a rat model of adoptive transfer experimental allergic 
encephalomyelitis (AT-EAE). Macrophages were labeled in situ by intravenous 
injection of PFC emulsion (perfluoro-15-crown-5-ether). However, this novel 
method has not drawn much attention until Ahrens et al. applied in vitro PFC 
labeling on dendritic cells and demonstrated the capability of 19F-MRI and 19F-
MRS in monitoring the distribution and migration of labeled cells in vivo in mice 
in 2005. Shortly thereafter, in vivo 19F-MRI and MRS for cell tracking have 
gained much renewed interests. Both the in situ and in vitro labeling approaches 
of PFC emulsion have been applied in various animal models in both high 
magnetic field (11.7 T) and clinical (1.5 T) field strength. Similarly to the method 
demonstrated by Noth et al., Flogel et al. have shown the feasibility of imaging 
inflammation in cerebral stroke and non-reperfused MI in mouse models by 19F-
MRI at 9.4 T, after in situ labeling of phagocytes in peripheral blood by using 
PFC emulsion121. They also applied this method on early detection of 
inflammation in lungs122, allograft heart rejection123 and rheumatoid arthritis in 
mouse models. The in situ labeling method is simple, avoiding potential risks of 
altering delicate functions of cells by in vitro manipulation. However, it has 
limited applications mainly on labeling phagocytes in circulating blood. Therefore, 
the in vitro PFC labeling strategy is often needed for cells without strong 
phagocytotic capability (e.g. T lymphocytes, progenitor cells, tumor cells). After 
in vitro labeling by PFC, Srinivas et al. demonstrated in vivo imaging and 
absolute quantification of diabetogenic T cells homing to the pancreas in the 
nonobese diabetic mouse, an established model of type 1 diabetes124. This 
approach has been further extended to trace transplantation of progenitor cells. 
Ruiz-Cabello showed that neural stem cells could be visualized by 19F-MRI till 
Day 14 after transplantation in mouse brain125. In addition, Partlow and colleagues 
demonstrated that cells labeled by PFC could be detected by 19F-MRI at a clinical 
1.5T MRI scanner. They also showed the capability of 19F-MRI to distinguish two 
populations of stem cells labeled with two different PFCs by using spectral 
discrimination at 11.7 T117. Being highly specific due to the lack of background 
signal, 19F-MRI for cell tracking shares the advantage of nuclear labeling, but is 
superior in providing precise anatomical localization and tissue characterization 
by seamless and straight forward registration with 1H-MRI. 
 
Currently, no apparent bio-effects were observed on viability and function of 
dendritic cells and mononuclear cells after PFC incorporation, either in vitro or in 
vivo 115, 117. 
 
As a non-specific labeling, 19F agents and iron oxide nanoparticles share some 
similar shortcomings such as dilution of intracellular labeling following cell 
division and passing of contrast agents to surrounding cells. Besides the 
availability of 19F coils, software modifications are needed to adapt conventional 
1H-MRI systems working for 19F imaging.  Moreover, 19F labeling is not as 
sensitive as iron oxide labeling in general. Despite the above, the application and 
development of 19F-MRI and MRS for cell trafficking have been carried out in a 
variety of institutes and manufactures. To increase sensitivity of 19F labeled cell 
detection, some of the iron oxide labeling strategies may be adopted. For example, 
transfection agents (TA) have been shown to achieve 26-fold-increase of 
intracellular 19F loading115. Moreover, the addition of Gd-DTPA administered 
intravenously shortens 19F-T1, which may enhance 19F signal intensity and reduce 
imaging time. The increasing magnetic field strength of clinical MR scanners 
should allow a faster and more sensitive cell tracing with 19F-MR imaging and 
spectroscopy.  
 
2.3.1.4 Strategies to increase intracellular loading of tracer/contrast agents 
For cellular MRI, the minimal number of cells to be detectable relies in part on the 
average intracellular loading of MR tracer/contrast agents. Given the same coating 
material, it has been shown that the efficiency of iron labeling increases with the 
increasing size of iron oxide nanoparticles126, probably due to the increase of 
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phagocytosis and endocytosis. However, it is unclear if a similar relationship 
applies to PFC emulsion labeling. Moreover, the coating materials may influence 
the cellular internalization of tracer/contrast agents127.  Higher iron loading may 
be achieved by increasing the dose of SPIO and prolonging incubation time. 
However, impaired cell viability and proliferation were observed in some of these 
settings, probably resulting from elevated levels of free radical. In addition, the 
majority of cell types used for stem cell research are non-phagocytes, which are 
not ready to uptake SPIOs or only internalize these nano-particles at a very low 
rate through pinocytosis. Therefore, efficient methods to facilitate cellular uptake 
of MRI tracer/contrast agents are needed. 
 
In the current stage, a combination of SPIO particles and polycationic transfection 
agents (TAs) is the most widely applied strategy to enhance the efficiency of iron 
oxide labeling128. Coated by negative charged polymeric, most SPIO particles do 
not spontaneously attach to the negatively charged cellular membrane. Being 
developed for facilitating macromolecule uptake into cells, transfection agents are 
highly positive charged macromolecules. They form complex with SPIO upon 
proper preparation. This positive charged complex of SPIO and TA spontaneously 
attaches to cellular membranes through electrostatic interaction and effectively 
shuttles SPIO particles into cells by endocytosis128.  
 
Unfortunately, the production of the two US Food and Drug Administration (FDA) 
approved SPIOs, Feridex I.V.® (also known as Endorem® and ferumoxides) and 
Resovist® (also known as Cliavist®), have been discontinued in 2008 and 2009, 
respectively. After that, Thu et al. proposed a new means that combines three 
FDA-approved drugs—ferumoxytol, heparin and protamine—in serum-free 
medium to form self-assembling nanocomplexes that effectively label cells for 
MRI cell tracking129. 
 
2.3.1.5 Bio-effects of Cell labeling with TA 
Cell labeling with iron oxide holds promise for rapid translation from bench to 
bedside. However, extensive toxicity tests and pre-clinical examinations are 
required for every protocol and cell type before clinical application. The FDA-
approved SPIO agents (Feridex®, Resovist® and Endorem®) are cleared mainly 
by the reticuloendothelial system, which is capable of metabolizing excess iron. 
However, non-phagocytic cells may not tolerate intracellular iron overloading. 
Additionally, the SPIO and TA complex is considered as a combination of two 
FDA-approved agents; therefore, further regulatory approval is required. A 
variety of cell types did not exhibit significant changes in viability, proliferation, 
differentiation and other vital functions after magnetic labeling with SPIO-TA 
combinations. However, Kostura et al. observed a dose-dependent inhibition of 
chondrogenetic differentiation in human mesenchymal stem cells (MSC) using a 
Feridex-Poly-L-lysine (PLL) complex labeling but not with solo treatment of 
PLL130.  Arbab et al. on the other hand reported that MSC chondrogenetic 
differentiation was affected only when Feridex-PLL complexes were not 
completely washed away before differentiation131. Most likely, residual Feridex-
PLL complexes sticking on cellular membranes may be responsible for the 
impaired differentiation132. Although this controversy has not been fully 
elucidated, it underscores the necessity of careful evaluation on labeling methods 
of the cell type intended to be used before clinical trials. Caution must be taken to 
draw preliminary conclusions from pre-clinical studies when cell labeling 
procedures are applied. 
 
Besides combining TAs, other approaches have been explored to improve SPIO 
internalization. Most of them rely on modification of the surface coating of 
particles. For instance, iron oxide loading was significantly increased when 
monoclonal antibodies were conjugated to SPIO to target specific receptors on 
cellular membrane surface. The intracellular uptake of SPIOs was increased by 
endocytosis mediated by receptor binding133. In addition, magnetoelectroporation 
devices were used to enhance the internalization loading of SPIO. Originally, 
these devices were developed to increase the penetration of DNA and 
chemotherapeutic drugs through cellular membranes. Walczak et al. demonstrated 
that magnetoelectroporation devices could quickly create intracellular endosmosis 
containing SPIO particles without the aid of TAs in various non-phagocyte 
populations134, 135. However, a recent report suggested that the in vitro 
differentiation of embryonic stem cells may be affected by the combination of 
magnetoelectroporation and ferumoxide, although cellular viability, proliferation 
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and apoptosis were not affected136. Therefore, further investigation is warranted to 
assess the bio-effects of these cellular label methods in vitro and in vivo. 
 
2.3.1.6 Detection sensitivity of MRI cell tracking 
The sensitivity of MRI cell tracking is determined by various factors: the type of 
cellular tracer/contrast agent, the intracellular loading of tracer/contrast agent, the 
MRI sequence, the spatial resolution, the magnetic field strength and the 
heterogeneity of tissue background etc.  
 
Among the several available cellular tracer/contrast agents, iron oxide particles 
deliver the highest sensitivity for MRI cell tracking when Gradient Echo (GE) 
sequence is applied, especially with high spatial resolution at higher magnetic 
field. However, its sensitivity is significantly reduced when background tissue has 
low proton density e.g. in lungs or original susceptibility effects e.g. hemorrhagic 
MI. It has been demonstrated that as few as 100 transplanted cells in the rat brain 
could be clearly seen by USPIO labeling, using a 3D GE sequence, a 98µm 
isotropic resolution and an intracellular iron load of approximately 7.1pg Fe/cell 
at 17.6-T137. The feasibility of single cell detection in vivo has also been 
demonstrated by MPIO labeling. At 4.7-T, single macrophages labeled by MPIO 
could be detected in vivo in an allograft heart rejection model in rats with an in-
plane resolution of 156µm138. A few studies reported that single cells labeled by 
iron oxide particles could be visualized in vivo in small animal models at 1.5-T. 
But these were done in static organs, such as the brain107. It is very challenging to 
achieve such goal in the beating heart at clinical MRI scanners, because motion 
artifacts, relative low signal to noise ratios and a large voxel size may all seriously 
hamper the detection sensitivity. In a pig model of acute MI, Hill et al. found that 
a minimum of 1×105 intramyocardially injected mesenchymal stem cells could be 
detected by a 1.5-T clinical MR, when the average iron loading was about 
200pg/cell107. The feasibility of visualizing SPIO labeled cells has also been 
explored after intra-vessel delivery. Baklanov et al. identified comparable 
hypointense signals in the infarct zone after intracoronary infusion of 
mononuclear bone marrow cells (BMCs) labeled by Feridex139. However, it seems 
that MRI is unable to detect cells labeled by iron oxide particles, when they are 
administrated intravenously140. Efforts have been made to increase the specificity 
of MRI cell tracking with iron oxide particles against heterogeneous tissue 
background. The group of Fayad proposed an appealing MR sequence, named 
‘Gradient echo Acquisition for Superparamagnetic particles with Positive 
contrast’ (GRASP), which creates positive rather than negative contrast of 
SPIO141. This method may overcome the interference of other sources of T2* 
effects. The hyperintense signal may increase the specificity of cell tracking. 
Alternatively, positive contrast of SPIO could be generated by applying spectral 
selective radiofrequency pulses to excite and refocus the off-resonance water 
surrounding the labeled cells142. 
 
Superior to iron oxide labeling, 19F-MRI is highly specific to detect PFC labeled 
cells due to a lack of detectable 19F signal background in living tissue. But 
generally it has a lower sensitivity in detecting a small amount of labeled cells, 
compared to iron oxide nanoparticle labeling detected by 1H-T2*WI. 
Theoretically, a minimum of 1018 19F atoms in each voxel is needed to reach 
sufficient signal to noise ratio on 19F-MRI. However, this number seems possible 
to be reduced by the integrated benefits of high magnetic field, efficient coils and 
extensive image averaging. Partlow et al. demonstrated that 2000 and 6100 cells 
could be detected by MRS and MRI at 11.7T, respectively, when intracellular 
loading of 19F atoms was 6×1012 /cell117. Moreover, the increased intracellular 
loadings of PFC could be achieved by addition of transfection agents. In 
comparison to in vitro incubation with PFC alone, Ahrens et al. observed 26 folds 
increase of intracellular PFC loading with addition of a transfection agent 
lipofectamine94. With such higher intracellular loading of PFC, significantly 
smaller amount of labeled cells could be detected by 19F-MRI. 
   
2.3.2 MR imaging of Pathophysiological Processes with Targeted 
Contrast agents  
The past two decades have witnessed tremendous progress in targeting MR 
contrast agents, which aim at highly specific and sensitive visualization of critical 
pathophysiological courses. Some of them also have therapeutic functions. 
Almost all categories of MR tracers/contrast agents (T1, T2/T2* and X-Nucleus 
etc.) have been used to link targeting/functional molecules for such goals. These 
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targeting molecules have a larger share in monoclonal antibodies and peptides. In 
cardiovascular diseases, inflammation (oxidative enzyme myeloperoxidase-
targeted)143, thrombosis (fibrin-targeted)144, 145, apoptosis (phosphatidylserine-
targeted)146, fibrosis/scarring147, vascular remodeling (oxidative enzyme 
myeloperoxidase-targeted)148 and angiogenesis (CD13-targeted)149 etc. important 
pathophysiological processes have been visualized by specific MR tracers/contrast 
agents. They involved atherosclerosis, ischemic injury, post infarction remodeling, 
heart failure and transplant rejection etc. models of diseases. 
 
2.3.3 Manganese Enhanced Cardiac MRI 
Calcium ions are regarded as the most important among the ions involved in the 
excitation-contraction coupling, a process from electrical excitation of the 
cardiomyocyte to contraction of the heart. Calcium ions in cardiomyocyte are in a 
dynamic yet delicate balance, created by multiple interacting cellular systems that 
can be tuned by physiological modulators. During ischemia and after ischemia-
reperfusion, this balance is disturbed. Mishandling of calcium ions in 
cardiomyocyte is a central cause of contractile dysfunction in ischemic and non-
ischemic remote myocardium3, 14, 15, 150. In spite of the importance of in vivo 
relevance, our knowledge of cardiomyocyte calcium signaling is mostly from in 
vitro experimental setups, due to the difficulty of doing so in vivo. 
 
By using contrast agents based on manganese ions (Mn2+), CMR can detect the 
activity of calcium channels in cardiac myocytes in vivo. Mn2+ is a competitive 
inhibitor of Ca2+ influx. Extracellular free Mn2+ enters cardiac myocytes 
predominantly via the L-type channel on cellular membrane. It is also similarly 
regulated by agents that influence Ca2+ influx151. Once inside cardiac myocytes, 
manganese ions can be retained intracellularly at least for several hours. They are 
predominantly taken up by mitochondria152. The rest are believed to bind to 
macromolecules inside cells. The intracellular Mn2+ shortens T1 and induce 
enhancement on T1WI. Fully quantitative examination of Mn2+ uptake in 
myocardium has also been demonstrated by applying R1 mapping on the heart153. 
Unfortunately, Mn2+ enhanced CMR has limited application in clinics, mainly due 
to the concern of its toxicity to the heart and neurological system. Nevertheless, 
this approach gives us a means to investigate calcium handling in cardiac 
myocytes in vivo by MRI. The visualizations of myocardial stunning154, 
myocardial infarction155, 156 and alteration of inotropy157 etc. have been 
demonstrated by manganese enhanced MRI. In recent years, there has been 
growing interests in developing and applying R1 mapping on manganese 
enhanced cardiac MRI, aiming at obtaining insights of quantitative calcium 
signaling in vivo. Waghorn et al. were the first to apply this technique to 
investigate alterations in calcium homeostasis in myocardial infarct mouse 
model153. Further, they used the same method to assess calcium efflux of 
myocardium in mice158. 
 
In order to interpret manganese enhanced MR image and R1 mapping as a 
surrogate of calcium handling in cardiac myocytes, many fundamental questions 
need to be answered. For example, how R1 change in myocardium is related to 
infusion dose and infusion rate? Is the kinetics of manganese agents related to 
heart function, which in turn affect R1 enhancement in myocardium? 
 
 
2.4 Aims of the Thesis 
 
This thesis was aiming to explore the potential of cardiac MRI in investigating 
ischemia-reperfusion injury and MI healing in molecular and cellular level in vivo 
and non-invasively in small animal models. 
 
Dominated by innate immune responses, infarcted myocardium undergoes 
dramatic changes in tissue structure and composition during acute and sub-acute 
phases. Ideally, the healing process constructs a compact scar to sustain the heart 
function. In recent years, increasing amount of data from both animal models and 
patients suggested the critical role of blood monocytes in MI healing32, 33, 159. It is 
known that the tissue of reperfused MI is often highly heterogeneous, due to 
numerous factors (e.g. susceptibility to ischemia, ischemia-reperfusion injuries, 
inflammatory responses). There is still a lack of the knowledge concerning the 
spatial distribution of monocyte recruitment in heterogeneous tissue of reperfused 
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MI, in addition to its association to various indicators of poor clinical outcomes, 
for example MVO and IMH. In this thesis, Chapter 3 describes the successful 
application of fluorine-19 MRI cell tracking in unambiguous visualization of the 
spatiotemporal distribution of monocytes and their descendant macrophages in 
reperfused MI with microvascular obstruction and intramyocardial hemorrhage. 
Besides the patterns of monocyte infiltration, long-term functional outcomes were 
monitored by MRI and correlated to the collagen deposition in both infarcted and 
non-infarcted myocardium. Additionally, 19F cellular MRI was applied to monitor 
the therapeutic effects of atorvastatin against ischemia-reperfusion injury in vivo, 
in combination to MI tissue characterization by 1H-MRI. 
 
During the healing process of MI, remodeling also takes place in structure and 
function of non-infarcted myocardium. As one of the most important ions in the 
ion signal system of the heart, calcium signaling has been found altered in acute 
and chronic MI hearts. Due to technical challenges, calcium signaling of 
cardiomyocyte is primarily studied in single cardiomyocyte setting in vitro, which 
poses difficulty in tissue preparation and sometimes relevance to in vivo 
pathophysiology. We improved and applied a quantitative manganese enhanced 
MRI (MEMRI) method in both sub-acute and chronic MI rats, to probe the influx 
and efflux of calcium in infarcted and non-infarcted myocardium in vivo. In 
addition, fundamental questions concerning the relationship between the 
manganese ion infusion rate, its cumulative dose and the enhancement of the spin-
lattice relaxation rate constants in blood, myocardium and other tissues were 
addressed. 
 
The findings of the above experiments provide multifaceted views of the healing 
process in infarcted hearts, which could be valuable for improving the 
understanding of mechanisms that determine optimal outcomes of acute MI. 
 
  
 
 
Chapter 3 
 
Inflammation of Healing Myocardial 
Infarction Monitored by Cellular 
Fluorine-19 Magnetic Resonance 
Imaging 
 
3.1   Introduction 
 
The healing of myocardial infarction (MI) is a delicately orchestrated 
inflammatory process, in which monocytes are central effectors and regulators27. 
Recent studies from both animals and patients revealed that two subsets of 
monocytes, the inflammatory and reparative monocytes, of distinct but 
complementary function were recruited sequentially into MI zone and 
significantly influenced long-term outcomes32, 33, 159. Therefore, monocytes are 
thought to hold a promise as a diagnostic marker and treatment target in 
individualized therapy to achieve optimal MI healing and reduce the risk of heart 
failure27.  
 
However, the spatiotemporal distribution of monocytes in reperfused MI has not 
yet been well described32, 33, 159. The tissue of reperfused MI is known being 
heterogeneous; therefore, the repair of myocardium with varied severity of 
ischemia-reperfusion injuries might involve different patterns of monocyte 
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infiltration. In particular, microvascular obstruction (MVO) and intramyocardial 
hemorrhage (IMH) are distinct features of reperfused MI. They occur in a sizable 
number of acute MI patients after reperfusion therapy and are markers of severe 
ischemia-reperfusion injury. Both associating with large MI size and prolonged 
ischemia before reperfusion, they were found highly correlated20, 111, 160, 161 and 
have been proven to strongly indicate worse prognosis23, 70-72, 162. Because 
microvascular damage lags behind cardiomyocyte death, MVO and IMH are 
always confined in necrosis69. However, the distinction between IMH across a 
spectrum of MVO is not yet elucidated, neither have the clear mechanisms that 
underlie their important prognostic values been well understood.  
 
In vivo imaging of monocyte recruitment could help to gain deeper knowledge of 
the inflammatory process of reperfused MI healing, estimate outcomes and guide 
individualized therapy. Magnetic resonance imaging has superior spatial 
resolution and versatile contrast to allow for tissue characterization. It is an ideal 
imaging modality to detect MVO and IMH. In addition, it has been demonstrated 
that MRI was capable of monitoring cell migration in experimental models in vivo 
and non-invasively163. Recently, fluorine-19 MRI for cell tracking has attracted 
much interest, due to its unambiguous detection and quantitative nature94. It 
overcomes several limitations of iron oxide nanoparticle labeling, avoiding for 
instance the non-specific magnetic susceptibility effect in tissue background e.g. 
hemorrhage and has potential for future clinical use163. In the heart, Flogel et al. 
demonstrated that 19F-MRI could image inflammatory cells infiltrating occluded 
MI zones in mice121. We established the combined 19F cellular MRI and 1H-MRI 
to visualize the dynamic recruitment of monocytes to reperfused MI with IMH 
and MVO, which provides a unique window to observe the cellular innate 
immunity in response to ischemia-reperfusion injuries. 
 
In this study, the spatiotemporal recruitment of monocytes in reperfused MI tissue 
was unambiguously and non-invasively visualized by in vivo 19F-MRI cell 
tracking in rats. MI areas and the presence of IMH and MVO were characterized 
by 1H-MRI. The integration of these two observations allowed for investigations 
of the monocyte infiltration in various regions of reperfused MI during healing. 
The functional and morphological outcomes under conditions of MVO and IMH 
were also investigated. In addition, 19F/1H-MRI was applied to monitor the 
therapy of reperfused MI by atorvastatin, a medication with primary function of 
lipid lowering but recently found beneficially limiting MI size and improving 
outcomes, when given acutely at high dose. 
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3.2 Methods and Materials 
 
19F-PFC emulsion formulation and its systematic kinetics 
Adapted from a previously described protocol121, the PFC emulsion of 20% v./v. 
concentration was formulated by emulsifying perfluoro-15-crown-5 ether (CE) 
(Exfluor Research Corp., Round Rock, TX, U.S.A.) in 3% 3-sn-
phosphatidylcholine (Sigma-Aldrich, GmbH, Seelze, Germany) dispersed in 
phosphate-buffered saline (PBS). The emulsion was further homogenized by SLM 
Aminco French press with SA-073 minicell at 20,000 psi. (SLM Instrument, 
Rochester, U.S.A.). The lipid coatings of emulsion particles were stained by 
fluorescent dye Vybrant® DiD cell-labeling solution (Invitrogen, Damstadt, 
Germany). The particle size was measured by dynamic light scattering (DLS) 
(Particle Analyzer FPAR-1000, Otsuka Electronics Co., Japan) and expressed as a 
mean of 5 measurements ± standard deviation (SD). 
 
The mean life time (t-mean) of PFC emulsion in circulating blood was determined 
by measuring residual CE contents in blood samples with nuclear magnetic 
resonance spectrometer (Bruker Avance 400, Bruker BioSpin, Rheinstetten, 
Germany) at 376.5 MHz. Samples of 100μL blood were taken from 3 female 
Wistar rats (250g, Charles River, Germany) via tail vein at 1, 2, 3.5, 5, 7, 9.5, 12, 
26, 48 and 72 hours after i.v. injection of 650µl PFC emulsion/100g body weight. 
Trifluoroacetic acid (TFA) (Sigma-Aldrich GmbH, Seelze, Germany) served as a 
reference in 19F-NMR measurements. The t-mean of the PFC emulsion in 
circulating blood was derived by fitting the exponential equation: 
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to the measured 19F signal in blood (S(t)) and was expressed as a mean of 3 
measurements ± SD. 
 
Quantification of intracellular loading of 19F spins 
The pilot studies of flow cytometry on blood samples showed that PFC emulsion 
primarily labeled CD11b+ cells in circulating blood (mainly monocytes and 
neutrophils). Therefore, we quantified the intracellular loading of 19F spins in 
CD11b+ cells by NMR spectrometer on leukocytes separated from full blood of 3 
rats (female, Wistar, 250±30g, Charles River, Germany), 2 days after i.v. injection 
of PFC emulsion (650µl/100g body weight). Trifluoroacetic acid (TFA) (Sigma-
Aldrich GmbH, Seelze, Germany) served as a reference in 19F-NMR 
measurements. The total number of the pooled leukocytes was calculated by 
counting the leukocytes in 20µl sample volume with a hemocytometer. The 
number of CD11b+ cells was determined by the proportion of CD11b+ cells with 
flow cytometry. The mean intracellular loading of 19F spins in CD11b+ cells was 
calculated by averaging the absolute number of 19F spins in the sample by the 
absolute number of CD11b+ cells. 
 
Reperfused MI model 
In accordance with the guidelines for research animal care of our institute and 
approved by the local ethic committee, reperfused MI was induced in 24 rats 
(Wistar, female, 200±30g, Charles River, Germany) by ligation of the left anterior 
coronary artery for 120min and subsequent removal of the knot, via anterior 
sternotomy under isoflurane (Abbott GmbH, Wiesbaden, Germany) anesthesia. 
Three sham-operated rats underwent the same procedure, except for arterial 
occlusion. 
 
Flow Cytometry 
On Day 3, 7 and 14 after MI, 400µl fresh peripheral blood from 6 MI rats was 
taken for flow cytometric analyses. To analyze which cell populations were 
preferably labeled by PFC emulsion (tagged by DiD), the following monoclonal 
mouse anti-rat antibodies (mAbs) were used: anti-CD11b RPE (mainly labeling 
monocyte, neutrophil, macrophage and dentritic cells) (AbD Serotec, Oxford, 
UK), anti-CD3 FITC (labeling T lymphocytes) (BD Pharmingen, San Diego, CA) 
and anti-CD45RA FITC (OX-33, only labeling B lymphocytes) (BD 
Pharmingen). Briefly, single-color staining was done in 50µl PBS/0.1% bovine 
serum albumin (BSA)/0.02% NaN3. Cells were incubated with the mAbs for 15 
minutes at 4°C, washed twice in 200µl PBS/0.1% BSA/0.02% NaN3 and finally 
subjected to erythrolysis in 100µl PBS/0.1% BSA/0.25% saponine for 15 seconds. 
Following a final wash with 200µl PBS/0.1% BSA/0.02% NaN3, the cells were 
subjected to analysis. Data were acquired by a LSRII flow cytometer (BD 
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Biosciences) using the FACSDiva Software (BD Biosciences). The software 
FlowJo (TreeStar Inc) was used to further analyze the acquired data. 
 
In vivo 19F/1H-MRI monocyte and macrophage tracking 
PFC emulsion was injected via tail vein on Day 1 after operation at a dose of 
650µL/100g body weight in 16 of the 24 MI rats. In vivo 19F/1H-MRI was 
performed longitudinally on Days 3, 7 and 14 at a 7-Tesla small animal scanner 
(Bruker BioSpin GmbH, Rheinstetten, Germany) using a double resonant  
birdcage coil (Bruker BioSpin GmbH). 
 
For 19F-MRI, turbo spin echo (TSE) MR sequence was applied with TR 750ms, 
TE 6.4ms, Turbo factor 2, number of averages 16 and spatial resolution (SR) 
1×1×2mm. The image acquisition time was 20-30min, depending on the cardiac 
and respiratory frequencies. For 1H-MRI, MVO was identified by early (1-10min) 
and late Gd-DTPA (0.3mmol/kg) enhancement (after 10min) using segmented 
inversion recovery fast low angle shot (FLASH) sequence (TR 1000ms, TE 
1.69ms, inversion time 450ms, in-plane resolution 0.312×0.312mm and slice 
thickness 1mm); IMH regions were detected by 1H-T2*WI with multi-echo 
Gradient Echo (GE) sequence (TR 150ms, TE ~3/6/9/12ms, in-plane resolution 
0.156×0.156mm or 0.156×0.312mm, and slice thickness 1mm); MI regions were 
determined by late Gd-DTPA enhancement using the same MR sequence and 
parameters as that for MVO; regional and global contractile functions were 
appreciated on multi-slice Cine MRI (12 or 24 frames per RR interval, flip angle 
30°, in-plane resolution 0.312×0.312mm and slice thickness 1mm). Normalized 
by an external PFC reference,  the 19F signal intensities in MI zone on Days 3, 7 
and 14 were compared. In addition, the normalized 19F signal intensity in MVO 
region was compared to that in MI area with IMH but absent of MVO on Day 14.  
 
Morphological and functional outcomes of MI with MVO and IMH 
In order to examine if MI hearts with MVO would have differential long-term 
outcomes, in comparison to those involving IMH but absent of MVO, MI rats 
under these two conditions (MI involving MVO: n=3; MI with IMH but absent of  
MVO: n=5) were followed by 1H-MRI on Days 3 and 28 post-MI. The initial MI 
size was assessed by late Gd-DTPA enhancement on Day 3. Heart function was 
determined by multi-slice Cine covering the entire LV. LV end diastolic volume 
(LVEDV), LV end systolic volume (LVESV), stroke volume (SV), ejection 
fraction (EF), cardiac output (CO) and cardiac mass (CM) were derived from Cine 
MRI acquired on Day 3 and Day 28 post-MI. The recovery of heart function was 
examined by the change of those parameters over time (Day 3 to Day 28). Hearts 
were excised for histology and immunohistochemistry after MRI on Day 28. 
 
Monitoring therapy of atorvastatin on acute reperfused MI with combined 
19F/1H-MRI 
Additional 5 MI rats were treated with atorvastatin (I.G., 100mg/Kg) 24h and 1h 
before MI operation. MI operation procedures were the same as previously 
described. The in vivo and ex vivo 19F/1H-MRI protocol was identical to the 
monocyte tracking experiments. IMH served as a marker of severe microvascular 
injury of ischemia-reperfusion. The signal intensity of 19F-MRI was a surrogate of 
the intensity of inflammation. 
 
Ex vivo 19F/1H-MRI 
After the last in vivo MRI, hearts were excised and underwent ex vivo 19F/1H-MRI 
before freezing (-80°C) or formalin (4%) fixation. For 19F-MRI, TSE sequence 
was applied with the following MR parameters: TR 4000ms, TE 5.4ms, Turbo 
factor 20, number of averages 13, and SR 0.375×0.375×0.5mm or 
0.375×0.375×1mm. For better visualization of the anatomy and IMH severity, 1H-
T2WI was acquired by 1H-TSE sequence with the following MR parameters: TR 
2500ms, TE 18ms, Turbo factor 4, in-plane resolution 0.117×0.117mm, and slice 
thickness 1mm and 0.5mm.  
 
MRI data post-processing 
MR image post-processing was performed by using MATLAB (The MathWorks 
Inc., Natick, USA) and Paravision 4.0 (Bruker BioSpin GmbH, Rheinstetten, 
Germany). 
 
Histological examination 
Sections of myocardium underwent hematoxylin and eosin (H&E) staining for 
determination of myocardial destruction and inflammatory cell infiltration. By a 
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three-step staining procedure in combination with biotinylated secondary antibody 
anti-mouse IgG (Vector Laboratories, Inc., Burlingame, CA, USA), 
immunohistochemical staining with mouse anti-rat ED1 monoclonal antibody 
(AbD Serotec) was applied on cryo-sections to detect monocytes and 
macrophages in MI zone. ED1 mAbs specifically recognize the antigen that is 
expressed predominantly on the lysosomal membrane of monocytes and 
macrophages in rats. The brown color was developed by the 3,3'-
Diaminobenzidine (DAB) substrate KIT for peroxidase (Vector Laboratories), 
after ED1 monoclonal antibody binding. The nuclei were counter-stained with 
haemalaun. The same treatments were performed on Paraffin fixed heart tissue to 
detect monocytes and macrophages in MI zone, in addition to antigen retrieval by 
heat before antibody incubation. For quantification of monocytes and 
macrophages in MI area, the antigen was visualized by FITC via avidin and 
streptavidin conjugates. With ImageJ (NIH, U.S.A.), the density of 
monocyte/macrophage infiltration was calculated and expressed as the relative 
area of FITC signal on 3-6 fluorescent pictures/tissue slide of 
immunohistochemistry (IHC) staining at 200 folds magnification. Intramyocardial 
hemorrhage was identified by Perl’s Prussian blue (PB) staining to detect the 
presence of excessive iron contents. PB was performed on tissue section of 30μm 
thickness; all other histology and immunohistochemistry were done on tissue 
sections of 8μm thickness. 
 
For the 28 days follow-up hearts, H&E, Picrosirius Red (PSR) and ED1 IHC were 
performed on cryo-sections to examine tissue destruction, collagen formation and 
distribution of macrophages, respectively. Quantification of collagen deposition 
was performed on PSR staining with bright field microscopy. The Red, Green and 
Blue (RGB) stack and thresholding functions of ImageJ were applied to segment 
the red-stained regions (collagen fibers on PSR staining) on microscopic photos. 
In both infarcted (replacement fibrosis) and non-infarcted (interstitial fibrosis) 
segments, the collagen volume fraction was expressed as the red-stained region 
divided by the area of myocardial tissue on the photo in percentage. The collagen 
fiber hue in MI zones was analyzed on photos of PSR staining illuminated by 
circularly polarized light, according to the method described by Rich and 
Whittakar164. As the collagen fiber thickness increases, the color of fibers evolves 
from green to yellow, orange and red. The proportion of the four colored fibers 
were calculated based on the following hue definitions: red 2-9 and 230-256, 
orange 10-38, yellow 39-51 and green 52-128. 
 
Confocal microscopy 
Confocal microscopy was applied to examine the distribution of PFC emulsion in 
MI zone, 14 days post-MI. After fixation with acetone and blockage with PBS 
containing 10% horse serum, cryo-sections of MI hearts (20µm) were incubated 
with the mouse anti-rat ED1 monoclonal antibody (AbD Serotec) overnight at 
4°C. Then a biotinylated secondary antibody was added for 1 hour incubation, 
before incubating with streptavidin FITC and staining the nuclei with DAPI. 
Control sections were processed identically, with the exception of omitting the 
incubation with the primary antibody. After ED1 immunohistochemical staining, 
cryo-sections of myocardium underwent serial scans with a thickness of 0.5μm, 
by a Leica TCS SP5 confocal laser-scanning microscope (Leica Microsystems, 
Mannheim, Germany). A 40× HCX PL Apo objective was applied. Monocytes 
and macrophages were identified by the green fluorescent FITC (intracellular) and 
the PFC emulsion was tagged by the near infrared fluorescent DiD. 
 
Detection sensitivity and quantification of 19F-MRI 
To determine the detection limit of 19F-MRI and the correlation between the 
concentration of 19F atoms and its 19F signal to noise ratio (SNR), a phantom 
study was performed on Eppendorf tubes containing the following concentrations 
of PFC emulsion suspended in 1.5% agarose: 0.35, 0.7, 1.4, 2.1, 2.8, 3.5, 7.0 and 
10.4 (×1016) 19F atoms / voxel. Parameters of 19F- and 1H-MRI were identical to 
those of in vivo MRI, except for the higher spatial resolution of 0.11×0.11×1mm, 
in order to reduce the number of 19F atoms/voxel. The SNR of each concentration 
was calculated and expressed as mean±SD of 6 MRI scans. The concentration of 
19F atoms versus its SNR value was plotted and the Pearson correlation coefficient 
was derived from the linear fit. SNR≥3 was considered as detectable. The limit 
of detection on PFC labeled blood monocytes was determined by converting the 
minimal detectable number of 19F atoms to the equivalent number of PFC labeled 
blood monocytes 2 days after i.v. injection of PFC emulsion. 
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19F signal impairment by susceptibility effects 
When in proximity to PFC, degraded hemoglobin contents may shorten 19F-T2 
and attenuate 19F signal intensity on T2-weighted 19F-TSE images. To 
quantitatively study the influence of magnetic susceptibility effects on 19F-T2 and 
the signal intensity on 19F-T2WI, we created a scenario in which iron oxide micro-
particles and PFC emulsion coincided within the same Kupffer cells in liver. 
Micrometer-sized iron particles (MPIOs, 4mg Fe/kg) (Bangs Laboratories, Inc.) 
were injected i.v. in 3 rats (Wistar, female, 250±25g, Charles River, Germany), 
which have previously received i.v. injections of 650µl PFC emulson/100g body 
weight. MPIOs are known to induce strong susceptibility effects and allow for 
single particle detection with 1H-T2*WI MRI165. 19F-T2WI (TSE) and 1H-T2*WI 
were acquired in vivo on the same image plane of the liver in the same animal 
before and after MPIO injection. After in vivo MRI, livers were excised and fixed 
in 4% paraformaldehyde for quantification of the influence of local magnetic 
susceptibility on 19F-T2, compared to another 3 livers from rats with only PFC 
emulsion injection (0.65ml/100g body weight) but not MPIO. For 19F-T2 maps, 
we applied multiple spin echo (MSE) sequence with TR 2100ms, TE 5ms and 150 
echo images. 
 
The T2* effects of MPIO in liver and that of IMH in MI were compared by their 
reduction on SNR in the homing tissue. In liver, the decrease of SNR was 
determined by (SNRpost – SNRpre) / SNRpre, where SNRpre and SNRpost stand for 
the SNRs in liver before and after MPIO injection on 1H-T2*WI (TE 6ms), 
respectively. In MI hearts (n=6), the decrease of SNR was determined by 
(SNRIMH – SNRremote) / SNRremote, where SNRIMH and SNRremote stand for the 
SNRs in IMH area and remote non-infarcted myocardium (septum) on 1H-T2*WI 
(TE 6ms), respectively. Normalized by the 19F signal intensity of an external PFC 
reference, the 19F signal intensities in liver before and after MPIO injection were 
compared.  
 
Statistics 
Results were expressed as mean±SD. Student t-test or repeated measures ANOVA 
was applied to examine the significance of difference in variables, when 
appropriate. P<0.05 was considered significantly different in statistics.  
3.3 Results 
 
PFC emulsion, its kinetics and intracellular loading of 19F 
The average diameter of PFC emulsion was 228.1±5.8nm. In circulating blood, 
the average t-mean of PFC was 12.05±2.15 hours. 48 hours after injection, most 
PFC was cleared out from circulating blood. 72 hours after injection, no 19F could 
be detected in blood by NMR spectrometer (Figure 3.1a). Two days after PFC 
emulsion injection, the mean intracellular loading of 19F spins was 3.8x1012 in 
blood monocytes (Figure 3.1b). 
 
 
Figure 3.1 In vivo kinetics and intracellular loading of PFC emulsion. (a): A 
representative clearance curve of PFC in circulating blood. Black arrows indicate that 
PFC was almost cleared out from blood 48 and 72 hours after injection (b): NMR 
spectroscopy of leukocytes separated from full blood of rats, 2 days after i.v. injection 
of PFC emulsion. The peak at -92ppm was contributed by CD11b+ cells labeled 
by PFC. The peak at -75.5ppm was the signal from the reference TFA. 
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Reperfused MI model and sham-operated animals 
In the 16 MI rats that were injected with PFC emulsion 1 day after MI, 15 of them 
developed IMH, among which 5 animals had MVO accompanied by IMH. None 
of the 3 sham-operated rats had MI. In the 8 MI rats assigned to the 28 days 
follow-up studies (without PFC emulsion injection), three of them developed 
MVO accompanied by IMH and the rest 5 of them had IMH absent of MVO. 
 
Flow cytometry 
On Day 3, 32±8.1% circulating leukocytes were labeled by PFC emulsion, as 
indicated by their fluorescent label DiD (Figure 3.2a). In addition, almost all the 
DiD+ cells were CD11b+ (Figure 3.2b), whereas CD3+ (T cells) and CD45RA+ 
cells (B cells) were negative for DiD. The proportion of PFC labeled CD11b+ 
cells in blood remained 100% on Day 7, although the amount of the internalized 
PFC decreased, as indicated by the shift of DiD fluorescent histogram (Figure 
3.2c). On Day 14, no DiD could be detected in CD11b+ cells from blood. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Flow cytometry of blood CD11b+ cells labeled by PFC in a representative 
animal. (a): 3 days after MI, PFC (DiD+) was detected in 32.4% of blood leukocytes. 
(b): Almost all PFC-labeled leukocytes were CD11b+. (c): When gating on CD11b+ 
cells, the fluorescent histogram of DiD showed that all CD11b+ cells were labeled by 
PFC (DiD+) on Day 3 (blue) and Day 7 (green). The control histogram in red 
represents DiD signal from blood CD11b+ cells of rats without PFC emulsion 
injection. The shift of DiD fluorescent histogram suggests a decrease of PFC 
intracellular loading from Day 3 to Day 7. 
In vivo 19F/1H-MRI 
By overlaying 19F images on corresponding 1H-MR images, the origin of 19F 
signal could be precisely determined. 19F signal emerged from MI zones but 
sometimes appeared smaller than the hyperintense areas on late Gd-DTPA 
enhancement. IMH was always confined in MI zone (Figure 3.3). MVO was 
found in the core of MI and accompanied by IMH (Figure 3.4). 
 
Importantly, 19F distributed inhomogenously in MI zone. When MVO was absent 
(Figure 3.3), the intensity of 19F signal appeared in response to the severity of 
ischemia-reperfusion injury: the more intense 19F signal distributed in MI core 
with severe IMH, where serious microvascular injury and myocardial necrosis 
occurred; the less intense 19F signal was found in MI regions without or with less 
severe IMH as well as in peripheral MI regions. However, 19F signal was  
attenuated in MVO areas, where severe necrosis was accompanied by IMH. 
Normalized by the 19F signal of an external PFC reference, the 19F signal was 
significantly lower in MVO regions than in IMH areas not involving MVO 
(p=0.001) (Figure 3.4). 
 
The spatial distribution of 19F signal in MI zone was similar on Days 3, 7 and 14, 
with the tendency of shrinkage in volume. Normalized by the 19F signal of an 
external PFC reference, the signal intensity of 19F was highest on Day 3, and 
decreased significantly (p=0.048) by 24% on Day 7. Day 14 saw a further 
reduction of 14% in 19F signal intensity, which was significantly lower than that 
of Day 3 (p<0.001) but insignificant to that of Day 7 (p=0.112) (Figure 3.3f).  
 
The contrast pattern of IMH could be highly dynamic. In 3 MI rats (19%), signal 
voids on 1H-T2*WI expanded in area and presented stronger susceptibility effects 
from Day 3 to Day 7, while the 19F signal decreased but consistently and 
unambiguously represented the distribution of labeled monocyte and macrophages 
(Figure 3.5). 
 
No abnormality of contractile function or hyperintensity on Gd-DTPA late 
enhancement was found in sham-operated hearts, nor was 19F signal. 
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Figure 3.3 Longitudinal observations on the spatiotemporal distribution of 19F signal in 
reperfused MI with IMH. (a): On Day 3 after MI, Gd-DTPA late enhancement 
delineated MI in anterior, lateral and inferiorlateral walls (green dash line). (b, c & d): 
The origins of 19F signal (hot color) were determined by overlaying 19F-MRI on Cine 
images. From Day 3 to 14, the 19F signal in MI zone distributed similarly, alongside the 
thinning and elongation of MI segments; but the overall intensity and volume of 19F in 
MI zone decreased over time. 19F signal was also seen in liver and operation wounds 
(OPW). (e): IMH appeared as signal voids (blue and green arrows) on 1H-T2*WI. The 
more intense 19F signal emerged in MI core with severe IMH (blue arrow) and the less 
intense 19F signal distributed in peripheral MI region with less severe IMH (green 
arrow). Note that 19F signal was not seen in part of the peripheral MI area without IMH 
in anterior wall (red arrow). (f): the column charter shows the evolution of the mean 19F 
signal intensity (normalized by an external PFC reference and adjusted to the baseline 
value on Day 3) in MI zone with time. (*p<0.05, ns: statistically not significant.)  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 In vivo 19F/1H-MRI of MI with MVO and IMH. (a): On Day 14 after 
infarction, a large IMH (white arrows) appeared as signal voids involving 
anteriorlateral, lateral and inferiorlateral walls on 1H-T2*WI. (b&c): early and late Gd-
DTPA enhancement delineated a large infarct (black arrows). MVO (blue arrows) 
located in the MI core in the lateral wall, presenting a sub-endocardial dark rim 
surrounded by brightly enhanced necrosis. (d): When superimposed on Cine-MRI, the 
corresponding 19F image showed that the 19F signal (hot color) intensity in MVO area 
(blue arrows) was absent or lower than in IMH areas without MVO. (e): Normalized 
by the signal intensity of an external PFC reference, the 19F signal intensity of MVO 
regions was significantly lower than that of IMH areas absent of MVO (*p<0.05). 
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Figure 3.5 The contrast evolution of IMH on 1H-T2*WI with time. (a&c): On long 
axis views of an infarcted heart on 1H-T2*WI, the signal voids of IMH appeared only 
at the apex on Day 3 (white arrow), but expanded along endocardium layer from apex 
to the entire inferior wall on Day 7 (white arrows). (b&d): In contrast, the 19F signal 
(hot color) attenuated but showed similar spatial distribution in apical and inferior 
segments (yellow arrows) from Day 3 to Day 7. 19F signal also appeared in ligation 
sites of MI (lg) and operation wounds (OPW). 
Figure 3.6 Ex vivo MRI and histology of MI heart with IMH absent of MVO (the 
same heart of Figure 3.3). Panel-A: Corresponding to the arrows of the same colors 
on in vivo MRI (Figure 3.3), the green, blue and red boxes indicate the peripheral MI 
area with IMH, the MI core with severe IMH and the peripheral MI region without 
IMH, respectively. (a&b): The distributions of 19F signal and IMH matched well with 
in vivo MRI (Figure 3.3d&e). (c&d) show the corresponding ED1 
immunohistochemistry and PB staining of (a&b). Black arrows indicate the match of 
excessive iron detected by PB (d) and IMH defined by ex vivo 1H-T2WI MRI (b). 
Ex vivo 19F/1H-MRI 
The distributions of 19F signal and IMH on ex vivo MRI correlated well with that 
on in vivo MRI. In hearts without MVO, the most intense 19F signal emerged in 
the MI core with severe IMH, the median and the least intense 19F signal appeared 
in MI zone with less severe IMH and in peripheral MI area without IMH, 
respectively (Figure 3.6, panel-A). Similarly to in vivo MRI, ex vivo MRI of 
hearts with MVO showed much attenuated 19F signal in MI regions corresponding 
to the MVO areas delineated by Gd-DTPA enhancement in vivo, but the reduction 
of 19F signal was more apparent in these regions. In addition, the areas with highly 
reduced or absent 19F signal appeared larger on MRI with higher spatial resolution 
(0.5mm slice thickness) (Figure 3.7, panel-A). In sham-operated hearts, neither 
wall thinning, nor IMH, nor 19F signal were observed on ex vivo MRI. 
 
Panel-A 
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Panel-B: (a, b & c) are ED1 immunohistochemistry from the box regions with the same 
frame color in Panel A. The yellow boxes indicate the location of the ×400 pictures in 
the same row (column-1/2/3). The density of macrophages (brown stained cells) on 
ED1 IHC correlated well with the 19F signal intensity on ex vivo 19F/1H-MRI (Panel A-
a). PB staining presented the severity of IMH. (b-1): The most abundant monocytes and 
macrophages were found in MI core with severe IMH (b-3). (a-1): Less abundant 
monocytes and macrophages were found in peripheral MI area with less severe IMH (a-
3). (c-1): Only sparse infiltrates of monocytes and macrophages appeared in peripheral 
MI region without IMH (c-3). (a-2&b-2): H&E staining shows the necrotic 
myocardium was mostly replaced by granulation tissue in MI zone with IMH. (c-2): In 
peripheral MI area without IMH, few inflammatory cells were found in myocardium 
with interlaced necrosis and viable cardiomyocytes. The ex vivo 19F/1H-MRI (Panel A-
a) as well as IHC and histology in the red box region (Panel-B c-1&2) revealed that the 
peripheral MI region without 19F signal on in vivo MRI (indicated by the red arrows on 
Figure 3.3) contained only few scattered monocyte and macrophage that couldn’t be 
detected by 19F-MRI. (black arrows: monocytes and macrophages, white arrows: 
necrotic myocardium, and blue arrow: viable cardiomyocytes) 
Panel-B 
Histological examination on hearts 14 days after infarction 
In hearts with IMH but absent of MVO 14 days after infarction, the densest 
monocyte/macrophage infiltration was found in the MI core accompanied by 
excessive iron contents (from severe IMH) as evidenced by PB staining in the 
same region on the neighboring tissue slice; the median dense infiltration of 
monocytes and macrophages was seen in peripheral MI area with less iron on PB 
staining; and few monocytes and macrophages appeared in peripheral MI region 
without PB+ staining.  H&E staining of those hearts revealed that infarct necrosis 
was mostly absorbed and replaced by granulation tissue (Figure 3.6, panel-B). 
 
In hearts with MVO 14 days after infarction, very few monocytes and 
macrophages were found by ED1 staining in the MVO corresponding region that 
showed attenuated 19F signal in MI core by ex vivo 19F/1H-MRI. This area 
resembles an “island” lacking monocyte/macrophage infiltration in hemorrhagic 
MI zones. The “island” contained necrosis with presence of (myo)fibroblasts and 
was accompanied by abundance of excessive iron contents, as was evident from 
H&E and PB staining of the neighboring tissue specimens. The approximate 
border dividing the “island” and the surrounding MI area could be seen on ED1 
IHC and H&E staining (Figure 3.7, panel-B).  
 
The above distribution patterns of macrophages and excessive iron contents in 
histology agreed well with those of the 19F signal intensity on 19F-TSE images and 
the hypointensity on 1H-T2WI of ex vivo MRI, respectively. Destruction of 
myocardium and infiltrates of inflammatory cells were not observed in sham-
operated hearts. 
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Figure 3.7 Ex vivo MRI and histology of MI heart with MVO accompanied by IMH 
(the same heart of Figure 3.4). Panel-A (a&b): Ex vivo MRI (slice thickness 1mm) 
correlates well with in vivo MRI on the morphology of IMH (between the black 
arrows) and the distribution of 19F signal (Figure 3.4 a&d). (b): Very weak or absent 19F 
signal (blue arrows) appeared in the area corresponding to the MVO region (in IM 
core) identified by Gd-DPTA enhancement on in vivo MRI (Figure 3.4 b&c). (c): With 
a higher spatial resolution of 0.5mm slice thickness, ex vivo MRI revealed that the area 
with attenuated 19F signal (blue arrows) in the MVO corresponding area was larger 
than it appeared on the slice with 1mm slice thickness (b).  
Panel-A 
 
 
 
Panel-B 
 
Panel-B shows the histology and immunohistochemistry of this heart. The green boxes 
are placed in the MVO corresponding area (blue arrows) detected by in vivo MRI. 
(a&e): cropped and enlarged images of Panel A-a&c. (b): PB staining revealed that the 
regions with shorter T2 on 1H-T2WI (a) had excessive iron contents. (c&d): The green 
dash lines indicate the approximate MVO border, where monocytes and macrophages 
started to infiltrate. In the MVO corresponding region (to the right of the green dash 
line), severe IMH (blue stained) was accompanied by few monocytes and macrophage 
(brown). (f) shows the higher magnification view of the approximate infiltration front 
of monocytes and macrophages (white arrows). (g): In the same region on the 
neighboring tissue section of (f), H&E staining shows the necrotic myocardium inside 
MVO area and the leukocytes with large round nuclei (some marked with yellow 
arrows) on the invasion front. In necrosis, numerous (myo)fibroblasts appeared. They 
are characterized by the spindle shaped nuclei. (h): In contrast to the necrotic 
myocardium, the morphology of viable myocardium stained by H&E in remote non-
infarcted myocardium is demonstrated. 
Figure 3.8 Confocal microscopy of infarct tissue with ED1-FITC IHC staining. ED1 
recognized a specific antigen that is expressed predominantly on the lysosomal 
membrane (intracellular) of monocytes and macrophages in rats. PFC emulsion (red, 
labeled by DiD) distributed in monocytes and macrophages (ED1+, green) in MI zone. 
DAPI was used to identify the nuclei. 
 
Confocal Microscopy 
On confocal microscopy, DiD-tagged PFC emulsion nanoparticles distributed 
intracellularly in monocytes and macrophages (ED1+) in MI (Figure 3.8). 
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Figure 3.9 19F signal intensity on 19F-TSE image was not affected by strong local 
susceptibility effects. (a1): 1H-T2*WI of the liver before MPIO injection. (a2): 19F-
TSE image of the liver before MPIO injection. (b1): 1H-T2*WI of the liver, 1 hour 
after MPIO injection. There was dramatic signal loss in the liver. (b2): 19F-TSE image 
of the liver, 1 hour after MPIO injection. The 19F signal intensity in liver was similar 
to that before MPIO injection. The column chart shows the mean±SD of the 
normalized 19F signal intensity in liver before (blue) and after (red) MPIO injection. 
19F signal was not impaired by strong susceptibility effects 
No significant reduction of 19F signal intensity has been observed when excessive 
iron oxide was present in liver Kupffer cells on in vivo MRI (p=0.52) (Figure 3.9), 
even though the susceptibility effect was significantly stronger than that of IMH 
in MI zone (p=0.004). Because the susceptibility effect depends on the micro-
distribution of iron and PFC, 19F-T2 is likely maximally shortened when MPIO 
and PFC were in the same Kupffer cells. In hemorrhagic infarction only a portion 
of paramagnetic hemoglobin-degraded products was internalized in monocytes 
and macrophages containing PFC. The rest stayed farther out (in extracellular 
space). On ex vivo MRI of the liver, 19F-T2 mapping revealed around 60% 
shortening of 19F-T2 time when MPIO was co-injected. Besides the moderate 
shortening of 19F-T2, the unaffected 19F signal intensity on 19F-TSE images was 
probably also a result of the short effective echo time applied during both in vivo 
(effective TE=6.4ms, Turbo factor=2) and ex vivo (effective TE=5.4ms, Turbo 
factor=20) MRI in our experiments. Therefore, the possibility of 19F signal 
reduction caused by the 1H-T2* effects in IMH areas could be excluded. In 
agreement with previous studies by other researchers, the 19F phantom experiment 
showed that the 19F signal intensity on TSE MRI was linearly correlated to the 19F 
spin concentration121, 124, 166. Accordingly, the 19F signal intensity allows for 
approximate comparison of the infiltration density of labeled monocytes and 
macrophages, independent of tissue background. 
 
 
 
 
 
 
Figure 3.10 Phantom studies determining the detection limit of 19F-MRI and the 
correlation between the concentration of 19F spins and the 19F SNR. (a): 1H-MRI of a 
phantom containing Eppendorf tubes filled with different concentrations of PFC 
emulsion suspended in 1.5% agarose, where a = 0.35, b = 0.7, c = 1.4, d = 2.1, e= 2.8, 
f = 3.5, g = 7.0 and h = 10.4 (×1016) 19F spins/voxel. (b): color scaled 19F-MRI shows 
the corresponding signal intensity of the PFC suspensions. Their SNR values are 
marked alongside. (c): The concentrations of 19F spins versus their mean SNR values 
are plotted. The values of standard deviation were not shown on the plots because they 
are smaller than could be visible on the plotting. 
Detection sensitivity and quantification of 19F-MRI 
The minimal detectable concentration of 19F atoms was 1.4-2.1×1016 19F 
atoms/voxel, reaching SNR of 2.8-4.3 (Figure 3.10 a&b). This detection limit is 
equivalent to 3684-5526 labeled blood monocytes (two days after 19F-emulsion 
injection) per voxel. The 19F signal was linearly correlated to the concentration of 
19F atoms with the Pearson correlation coefficient of 0.99 (Figure 3.10c). 
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MI with MVO and IMH: differential long-term morphological and 
functional outcomes  
The initial MI size was similar in both MVO and IMH groups (MVO vs. IMH = 
107.45±60.95µl vs. 85.14±34.84µl, p=0.52), as measured by multi-slice late Gd-
DTPA enhancement MRI on Day 3 after MI (Figure 3.11 Panel-A). On the same 
day, EF, LVEDV, LVESV, CO and LVM etc. functional index were similar 
between the two groups (Table 3.1). 28 days later, The MVO group had lower 
mean EF (33.3±8.2% vs. 45.5±11.8%, p=0.076) and higher mean LVM 
(0.68±0.17g vs. 0.53±0.12g, p=0.090) than the IMH group, with borderline p 
values (Table 3.2). However, the MVO group has significantly worsened pump 
function conversely to the improved EF of the IMH group, as evidenced by the 
change of EF (∆EF) between Day 28 and Day 3 (Figure 3.11 Panel-A, ∆EFMVO 
vs. ∆EFIMH = -7.2 ±3.7% vs. 4.13±4.6%, p=0.006). In addition, the MVO group 
demonstrated greater mean values of ∆LVESV (∆LVESVMVO vs. ∆LVESVIMH = 
0.216 ±0.215ml vs. 0.059±0.089ml, p=0.093), ∆LVM (∆LVMMVO vs. ∆LVMIMH 
= 0.18±0.13g vs. 0.056±0.123g, p=0.109), as well as ∆heart rate (∆heart rateMVO 
vs. ∆heart rateIMH = 30±30/min vs. -19±47/min, p=0.082), compared to the IMH 
group (Table 3.3). 
 
 
Table 3.1 LV volumes and function on Day 3 
 
 
 
Table 3.2 LV volumes and function 28 days post-MI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3 Changes of LV volumes and function 28 days after infarction 
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Figure 3.11 Panel-A MI size and functional outcomes of hearts with IMH and MVO. 
(a): MI size on Day 3. (b): ejection fraction (EF) on Day 3. (c): EF on Day 28. (d): the 
change of EF (∆EF) between Day 28 and Day 3. (*p<0.05, ns: statistically not 
significant.) 
 
 
 
 
Panel-A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Panel-B 28 days after MI, collagen volume fraction and collagen fiber 
hue analysis of MI hearts with IMH (n=4, one heart tissue was damaged before 
histological examination) and MVO (n=3). Bright field microscopic photography of 
picrosirius red (PSR) staining: (a) infarcted region of an MI heart with MVO, (b) 
infarcted area of an MI heart with IMH but absent of MVO, (d) remote non-infarcted 
myocardium (septum) of an MI heart with MVO and (e) remote non-infarcted 
myocardium (septum) of an MI heart with IMH but absent of MVO. Column charts 
show quantification of collagen volume fraction on bright field microscopy of PSR 
staining: (c) in infarcted regions and (f) in remote non-infarcted myocardium 
(septum). (h) Hue analysis of collagen fibers of MI zone in the MVO group and the 
group with IMH but absent of MVO. (*p<0.05, ns: statistically not significant.) 
Panel-B 
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In addition, the collagen contents in both MI zones (replacement fibrosis) and 
remote non-infarcted myocardium (interstitial fibrosis) were quantitatively 
examined in the MVO and IMH groups by PSR staining, 28 days after infarction. 
Derived from the bright field microscopic pictures of PSR staining, the collagen 
volume fraction in MI segments was significantly higher in the MVO group 
(MVO vs. IMH = 58.18±3.97% vs. 46.19±6.79%, p=0.043). Further analysis on 
the collagen fiber hues by circularly polarized light microscopy on PSR staining  
revealed that the replacement fibrosis of the MVO hearts contained significantly 
lower proportion of red collagen fibers (the thickest collagen fibers), in 
comparison to that of the IMH hearts (MVO vs. IMH = 4.10±2.94% vs. 
17.48±6.98%, p=0.028). The orange fibers were significantly higher in the MVO 
group (MVO vs. IMH = 83.86±3.0% vs. 74.27±3.5%, p=0.013). The proportions 
of the green and yellow collagen fibers (thin fibers) were similar in the two groups 
(Green fibers: MVO vs. IMH = 4.74±2.99% vs. 2.40±1.94%, p=0.26; yellow 
fibers: MVO vs. IMH = 7.31±2.98% vs. 5.85±2.89%, p=0.452). The mean value 
of the collagen volume fraction in remote non-infarcted myocardium (interstitial 
fibrosis) was greater in the MVO group than in the IMH group, without statistical 
significance (MVO vs. IMH = 4.18±2.43% vs. 1.97±0.27%, p=0.26). (Figure 3.11 
Panel-B) 
 
Monitoring therapy of atorvastatin in experimental reperfused MI 
19F-MRI visualized blood monocytes infiltrating infarcted myocardium in vivo in 
both atorvastatin treated and untreated MI rats (Figure 3.12, a1&b1). The 19F 
signal intensity correlated well with the density of monocyte/macrophage 
infiltrates quantified by ED1 IHC (Figure 3.12, c1&c2). Indicated by significantly 
attenuated 19F signal and proven by ED1 IHC quantification, the recruitment of 
monocytes and macrophages was significantly attenuated in the treated MI rats 
(Figure 3.11, b1,2&3), compared to the untreated (Figure 3.12, a1,2&3). Better 
preserved microvasculature in the treated rats was evident from significantly 
reduced volume of IMH, an indicator of severe microvascular injury (Figure 3.12, 
a4&b4). 
Figure 3.12 19F/1H-MRI monitoring atorvastatin therapy in reperfused MI in rats. 
A representative untreated MI rat: (a1): in vivo 19F/1H superposition; (a2): late Gd-
DTPA enhancement; (a3): ex vivo 19F/1H superposition; (a4): ex vivo 1H-T2*WI and 
Prussian blue (PB) staining of the boxed MI region. A representative atorvastatin 
treated MI rat: (b1): in vivo 19F/1H superposition; (b2): late Gd-DTPA enhancement; 
(b3): ex vivo 19F/1H superposition; (b4): ex vivo 1H-T2*WI and Prussian blue (PB) 
staining of the boxed MI region. (c1): column chart shows signal to noise ratio (SNR) 
of 19F-MRI in MI zones of the atorvastatin treated and untreated animals. (c2): 
quantification of monocyte/macrophage infiltrates in atorvastatin treated and untreated 
MI rats. (yellow arrows: 19F signal in MI zone; red arrows: MI regions; black arrows: 
IMH areas. OPW: operation wounds. *p<0.05.) 
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3.4 Discussion 
 
In this study, we present the first report of visualizing the dynamic recruitment of 
monocytes in vivo in reperfused MI with MVO and IMH by 19F/1H-MRI in rats.  
Monocytes were recruited inhomogeneously in reperfused MI tissue: their 
infiltration was highly attenuated in MVO regions; in absence of MVO, more 
intense monocyte infiltration was observed in areas with severe IMH. Compared 
to the group with isolated IMH, the MVO group exhibited worse long-term 
functional outcomes. 
 
Tissue heterogeneity of reperfused MI: emphasis on MVO and IMH 
Reperfused MI tissue is heterogeneous due to unequal ischemia-reperfuison 
injuries, susceptibility to ischemia and inflammation etc16. MVO and IMH occur 
in a sizable number of acute MI patients after primary percutaneous coronary 
intervention (PPCI)111, 160, 161. They are markers of ischemia-reperfusion injury. 
MVO refers to hypoperfused myocardial tissue despite the patent epicardial 
coronary vessel, due to functional or anatomical changes of coronary 
microcirculation20. A large amount of clinical data has convincingly shown that 
MVO negates the benefit of PPCI. It strongly predicts early adverse left 
ventricular remodeling and worse recovery of heart function in the long term, 
independent of MI size23. It is also correlated to higher risks of early post-MI 
complications, heart failure and mortality162. IMH is a phenomenon that red blood 
cells leak into the interstitium during reperfusion after necrosis and loss of 
capillary integrity during myocardial ischemia167. It indicates severe 
microvascular destruction and cardiomyocyte death69, associating with poor 
recovery of LV function and long-term clinical outcomes71, 72. However, 
conflicting results were reported on the independent prognostic value of IMH71, 72. 
It is still a debate whether IMH represents a marker of adverse ventricular 
remodeling beyond MI size, LV ejection fraction and MVO. MVO and IMH are 
highly correlated. It is believed that they are secondary phenomena that occur in 
necrotic myocardium rather than the cause of cardiomyocyte death69, 168. Both of 
them associate with large MI size and prolonged ischemia before reperfusion111, 
160, 161. However, the distinction between IMH across a spectrum of MVO is not 
yet elucidated. 
 
Previous studies on MVO and IMH mostly focused on molecular and cellular 
mechanisms during the first several hours of ischemia-reperfusion and their 
associations to long-term clinical outcomes. However, questions concerning how 
the healing process is affected in MVO and IMH, as well as the clear mechanisms 
that underlie their important prognostic values have not been answered. Partly 
determined by infarct size, the adverse LV remodeling is also a consequence of 
the rate of MI healing and the material properties of MI segments27, 45, which has 
been evident from the delayed healing and dramatically higher risks of ventricular 
aneurysm in steroid therapy during acute MI in dogs and patients169. MVO and 
IMH are both confined in necrotic myocardium. Their initial tissue components 
are presumably similar (mainly necrosis). Therefore, it is important to investigate 
how monocyte infiltration responses to various severity of ischemia-reperfuison 
injuries, in particular whether and how necrosis absorption and tissue reparation 
by monocytes are altered in MVO and IMH. 
 
Monocytes and macrophages were labeled by PFC and unambiguously 
detected by 19F-MRI 
With only one injection on Day 1, CD11b+ cells in blood were efficiently labeled 
by PFC emulsion at least till Day 7, a time window during which monocytes are 
recruited actively from blood to MI32, 170. CD11b is expressed in monocytes, 
macrophages, dendritic cells and granulocytes in blood. Macrophages and 
dendritic cells are rare in blood, and eosinophils and basophils are non-
phagocytes; therefore monocytes and neutrophils constituted the majority of the 
PFC labeled CD11b+ cells in blood to be recruited to MI. Considering that most 
neutrophils infiltrate MI during the first 24 hours after MI32 and that we injected 
PFC emulsion 24 hours after operation, the PFC labeled CD11b+ cells being 
recruited to MI tissue should mostly be blood monocytes. In addition, PFC 
emulsion only appeared in cytoplasm of monocytes and macrophages in MI areas 
on the fluorescent confocal microscopy (Figure 3.8). Therefore, the 19F signal 
emerging from MI regions was contributed primarily by PFC labeled monocytes 
and macrophages. Because 19F signal intensity was linearly correlated with the 
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density of 19F spins (Figure 3.10) and was not influenced by strong susceptibility 
effects with our imaging protocol (Figure 3.9), it indicated the relative amount of 
monocytes/macrophages in different MI regions, which was further proven by the 
good correlation of 19F signal intensity on ex vivo MRI and the density of 
monocyte/macrophage infiltration on ED1 staining (Figure 3.6). 
 
Dynamic distribution patterns of monocyte and macrophage in reperfused 
MI revealed by 19F cellular MRI  
19F-MRI revealed that the distribution of monocytes and macrophages was 
spatially similar on Days 3, 7 and 14 in reperfused MI, while the LV was 
undergoing dramatic wall thinning and chamber enlargement (Figure 3.3). In 
contrast, Flogel et al. found that the 19F signal positive regions increased in area 
over time during the first 6 days in occluded MI in mice121. This might be due to 
the different infiltration patterns of inflammatory cells in reperfused and occluded 
MI: in non-reperfused MI the front of immune cell infiltration starts from the 
borders of MI and progresses to the center, while in reperfused MI the invasion of 
neutrophils starts immediately upon reperfusion of the injured myocardium and 
lasts for around 24 hours. Shortly thereafter, lymphocytes and monocytes are 
recruited32, 171.  
 
In addition, we found that the 19F signal intensity was highest on Day 3, suggeting 
that the density of monocytes was the highest in MI tissue around 3 days after MI. 
This observation is in agreement with Nahrendorf et al.’s findings by flow 
cytometry to quantify immune cells in acute occluded MI in mice, that the total 
monocytes number was highest around Day 332. After monocytes differentiated 
into macrophages, PFC was still retained intracellularly. Then 19F signal 
represented the density of the sum of monocytes, macrophages and possibly a 
very small number of dendritic cells in MI. We found that the 19F signal 
intensities significantly reduced from Day 3 to Day 7 by 24% on, which is in line 
with Nahrendorf et al.’s results32 but in contrast to Flogel et al.’s observations that 
the 19F signal intensity gradually increased during the first 6 days in non-
reperfused MI in mice121. On Day 14, the mean 19F signal intensity further 
decreased from Day7 by about 14%. But the difference was insignificant. 
However, Nahrendorf et al. found a much more dramatic reduction (almost 90%) 
of the density of the sum of monocytes, macrophages and dendritic cells from Day 
3 to Day 16 in non-reperfused MI in mice by flow cytometry32. Further 
investigations are needed to determine whether the above discrepancies are 
contributed by different methods applied (19F-MRI rather than flow cytometry) to 
estimate cell number or/and the different MI models (reperfused and non-
reperfused MI) used. As a limit of the in situ labeling of blood monocytes by i.v. 
injection of PFC emulsion, the intracellular loading of PFC gradually decreased in 
circulating monocytes, as indicated by the flow cytometry results. This might 
complicate the interpretation of 19F signal changes. 
 
Spatial distribution of monocytes and macrophages in heterogeneous tissue 
of reperfused MI: highly impaired monocyte recruitment in MVO  
19F-MRI revealed that the density of monocyte and macrophage in MI zones was 
in response to the severity of ischemia-reperfusion injury when MVO was absent: 
the more intense 19F signal distributed in MI regions with severe IMH, an 
indicator of severe microvascular injury and therefore more tissue necrosis69; the 
less intense 19F signal intensity was found in MI area with less IMH; and the 
lower 19F signal in the non-hemorrhagic peripheral MI region, where necrosis 
interlaces with the viable myocardial tissue. Under the above circumstances, the 
number of the recruited monocytes and their decedent macrophages seems to 
match the amount of injured tissue to be removed and repaired (Figure 3.3&3.6). 
 
However, even 14 days after MI, highly impaired monocyte and macrophage 
infiltration was found in MVO regions, which was accompanied by severe IMH. 
Monocytes and macrophages are indispensable in MI wound healing. It has been 
shown in mice, when monocytes and macrophages were depleted in the first week 
after myocardial cryo-injury, the cell debris absorption in myocardium was 
delayed, furthermore the secretion of transforming growth factor-beta and 
vascular endothelial growth factor-A was reduced. As a result, neovascularization, 
myofibroblast infiltration, and collagen deposition were all decreased. Moreover, 
macrophage depletion resulted in a high mortality rate accompanied by increased 
left ventricular dilatation and wall thinning172. Delayed necrosis absorption and 
wound healing were also observed in patients when steroid therapies were applied 
during acute MI, resulting in significantly higher occurrence of aneurism169. In 
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our experiments, the MVO regions resembled ‘islands’ lacking monocytes and 
macrophages. Such a structure could be fragile and tend to develop profound wall 
thinning, LV enlargement and rupture. In addition, life threatening arrhythmia 
might be more likely to occur in such heterogeneous tissue with variable 
electroconductivities. 
 
In contrast, MI regions with IMH but not involving MVO seem to have 
“reasonable” monocyte and macrophage infiltrates. The differential innate 
immune responses to MVO and IMH without MVO suggest that even though 
being highly correlated and presumably similar in initial tissue composition 
(mainly necrosis), the subsequent healing processes in these two MI regions 
appeared differential at least in respect of monocyte recruitment.  
 
In the 28 days follow-up studies, the MVO group demonstrated significantly 
worse ∆EF in comparison to the IMH group, despite that the initial MI size and 
function were similar in the two groups. Advancing in parallel with healing, post-
MI LV remodeling is a complex, dynamic and time-dependent process, which 
involves differential alterations between the infarcted and non-infarcted 
myocardium. The early regional remodeling of the infarcted segments contributes 
significantly to global LV structural remodeling post-MI. The prolonged exposure 
of extensive unhealed MI tissue to mechanical deformation forces could lead to 
greater infarct expansion and promote LV dilatation in the MVO group. In the 
non-infarcted myocardium, the chronic LV pressure overloading could stimulate 
interstitial fibrosis, which increases the ventricular stiffness and impairs 
contractile function, resulting in progressively declined EF. Therefore, the lack of 
monocytes and macrophages in MVO areas could be responsible for the worse 
remodeling and function of the MVO group in the long term.  
 
Interestingly, the collagen volume fraction in the MI zones (replacement fibrosis) 
was significantly higher in the MVO group than in the group of IMH absent of 
MVO. It was sampled randomly in the entire MI regions, indicating the collective 
quality of scar formation. The higher collagen volume fraction in the scar seems 
to more strongly support ventricular morphology. However, the hue analysis of 
collagen fiber composition showed that the proportion of red fiber (the thickest 
fiber) was significantly lower in the MVO group. This result might suggest that 
the collagen fibers were less mature in the scar of MVO hearts on Day 28. 
Collagen is mainly synthesized and secreted by myofibroblasts. The synthesis and 
secretion of collagen by myofibroblasts are regulated mainly by mechanical 
stretching and various chemotactic factors produced by cardiac fibroblasts, 
proinflammatory cytokines secreted by monocytes, macrophages, T cells and mast 
cells. They are commonly found in granulation tissues, which typically grow 
inward from peripheral MI. We observed the presence of (myo)fibroblasts in the 
MVO corresponding area 14 days after MI. Further investigation is needed to 
explore the behavior of fibroblasts and (myo)fibroblasts in MVO regions during 
healing. In addition, it is to be determined how the highly impaired monocyte and 
macrophage infiltration in MVO regions during acute and sub-acute MI 
contributes to the patterns of collagen deposition in MVO hearts in the long term. 
 
The highly impaired monocyte and macrophage recruitment in MVO regions, 
which was associated with the subsequent different patterns of post-MI fibrosis 
and the worsened long-term outcome of MVO than IMH alone, suggests that 
MVO and IMH could be differential in the wound healing process. These findings 
might explain, at least partly, why MVO is associated with adverse LV 
remodeling and worse clinical outcomes, independent of MI size. 
 
Monocyte recruitmet in MVO: a potential diagnostic marker and therapeutic 
target 
Since MVO independently indicates worse outcomes of reperfused MI, to prevent 
and reverse MVO are thought to improve prognosis. Efforts have been made to 
reverse MVO in clinical trials, but the efficacy of achieving tissue perfusion in 
MVO is not clear173. Furthermore, since MVO areas primarily constitute of 
necrotic tissue, the reversal of MVO is not thought to rescue viable myocardium. 
Therefore, whether and how the improved tissue perfusion in necrotic 
myocardium of MVO indeed contributes to improvements of cardiac function and 
clinical outcomes is to be examined. From our findings, it seems reasonable to 
promote monocyte recruitment in the treatment of MVO, in order to accelerate the 
delayed wound healing and improve the compromised tissue property. The  
difference between MVO area and IMH region in monocyte recruitment perhaps 
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does not merely due to the insufficiency of tissue perfusion, because the 
infiltration of monocytes and macrophages peaked around Day 3-7 in non-
reperfused MI in rats170 and mice32, 121. Further investigations are needed to 
explore the signaling of inflammation in MVO and IMH regions. This might 
contribute to potential solutions for accelerating healing process of MI with MVO, 
by modulating  monocyte recruitments in MVO areas. 
 
Monitoring of atorvastatin’s therapy on reperfused MI 
The 1H-MRI findings support the hypothesis that the atorvastatin-associated 
beneficial effect of less cardiac muscle loss and adverse LV remodeling might 
result, at least in part, from the better preserved microcirculation in the area at risk 
after ischemia-reperfusion. Whether less monocyte and macrophage infiltration in 
MI was a result of a better salvaged area at risk due to the effect of atorvastatin on 
microcirculation, and/or it led to less endothelial and cardiomyocyte injury early 
after reperfusion still needs to be examined. In addition, the long-term benefit of 
such treatment on cardiac remodeling needs to be investigated. 
 
Advantages of 19F MR cell tracking 
Because 19F in living body is too rare to be detected by MRI, the labeled cells are 
the only source of signal. The unambiguity of 19F signal showed its advantage 
over iron oxide labeling in MR cell tracking in tissues with strong backgrounds of 
local T2* effects, for instance in reperfused MI with IMH. According to our 
results and other studies on large animal or humans, MRI defined IMH occurred 
in 25-100% reperfused MI, when ischemic assaults lasted for more than 2 hours 
before reperfusion72, 111, 174, 175. The MRI contrast features of IMH dynamically 
change, corresponding to the integrity of red blood cells, the oxygenation states of 
hemoglobin and the progress of hemoglobin degradation175. The evolution of IMH 
contrast further complicates the interpretation of MR cell tracking in hemorrhagic 
MI utilizing iron oxide particles111. However, the 19F signal was not influenced by 
strong local T2* effect and linear to the concentration of PFC; therefore, 19F-MRI 
allows for specific detection and easier quantification of labeled cells in IMH 
(Figure 3.5). In addition, 19F-MRI preserves the full capability of 1H-MRI for MI 
tissue characterization, while cell labeling by iron oxide particles may shorten T2 
and T2* of background tissue, which cloud the measurements of edema and IMH. 
Edema and IMH are important features of reperfused MI for estimating area at 
risk and the severity of ischemia-reperfusion injury, respectively. Moreover, 19F-
MRI has potential for clinical translation. CE and several other PFCs are 
biologically inert and their emulsions were approved for clinical use. As 
estimated, 4000-5500 CD11b+ cells could be detected by 19F-MRI (SNR=3) in our 
setups (Figure 3.1&3.10). Human hearts allow at least 250-folds larger voxel 
volume (5mm×5mm×20mm) than in rats (1mm×1mm×2mm). Therefore, it should 
be feasible to image labeled cells in patients.  
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3.5 Conclusions 
 
In reperfused MI, the monocyte recruitment was in response to the severity of 
ischemia-reperfusion injury, except for MVO regions, in which the distinct 
mismatch of the highly impaired monocyte recruitment and the severe ischemia-
reperfusion injury was found. In the long-term post-MI, we found significantly 
increased post-MI fibrosis in MI zones and worse functional recovery in MVO 
hearts, in comparison to IMH hearts absent of MVO. The healing process and 
functional outcome indicate that MVO and IMH are closely correlated but yet 
differential. The impaired monocyte recruitment and the likely lower rate of 
healing in MVO regions could contribute to its independent prognostic value of 
worse outcomes in the long term. Further investigations are needed to explore the 
role of fibroblasts and (myo)fibroblasts in the healing of MVO regions. It is to be 
determined how such impaired recruitments of monocytes/macrophages during 
acute/sub-acute MI are related to the increased post-MI fibrosis in the long term. 
 
The combined 19F/1H-MRI allowed for monitoring the modulation of myocardial 
monocyte infiltration and revealed a possible mechanism of an anti-inflammatory 
approach by atorvastatin. This platform might provide a novel and integrated view 
on tissue injury and its cellular innate immune response after ischemia-
reperfusion. It could contribute to gain new insights into the effects of anti-
inflammatory therapy in MI and has potential for clinical translation in acute MI 
patients in the future. 
 
 
  
 
 
Chapter 4 
 
Quantitative Manganese Enhanced 
Magnetic Resonance Imaging in 
Myocardial Ischemic Injury and Heart 
Failure 
 
4.1   Introduction 
 
Intracellular calcium ion (Ca2+) is a central regulator of cardiac contractility and 
viability176. To sustain intracellular homeostasis of Ca2+, the quantities of Ca2+ 
processed by various routes must balance: the influx of Ca2+ into the cell via the 
surface channels have to be matched by its efflux from the cell by the sodium-
calcium (Na–Ca) exchanger; additionally the quantity of Ca2+ released from 
internal sarcoplasmic reticulum stores via the Ca2+ release channels must be 
returned to the sarcoplasmic reticulum (SR) via the SR Ca-ATPase. When 
transient imbalance occurs, the depletion or augmentation of Ca2+ store might lead 
to inotropic adjustment. There are non-ignorable evidences showing the 
involvement of deranged Ca2+ handling in various scenarios of patholphysiology, 
for example myocardial stunning177, hibernation178, myocardial infarction150 and 
heart failure etc179. Despite its importance in physiology and pathophysiology of 
myocardium, Ca2+ signaling is predominantly studied in vitro in single cardiac 
myocyte settings, due to technical difficulties in measuring this signal in vivo. 
 71  
Manganese ions (Mn2+) are analogues of Ca2+. They can be taken up by cardiac 
myocytes151, 152. Extracellular free Mn2+ can compete with Ca2+, get through the 
voltage operated calcium channels on myocyte membrane and accumulate 
intracellularly in addictive manner152, 180.  Mn2+ is an excellent MR contrast agent, 
due to its ability to decrease both T1 and T2 of surrounding water. The MR 
relaxation rates (R1=1/T1 and R2=1/T2) are proportional to the effective 
concentration of Mn2+ in tissue153, 181. T1 weighted image (T1WI) is a favorable 
means for detection of Mn2+ accumulation in tissue, owning to its positive contrast, 
higher signal to noise ratio, higher contrast-to-noise ratio and the much larger 
tissue T1 than T2. In the heart, enhancement of myocardium on T1WI has been 
demonstrated in animal models by systematic administration of manganese 
chloride182, 183 and chelated manganese (Manganese dipyroxyl diphosphate, Mn-
DPDP)184. However, relatively large quantity of Mn2+ is needed to achieve 
significant enhancement on T1WI. In addition, the enhancement effect is a 
relative extent with non-ignorable fluctuations resulting from varied TR due to 
respiratory and cardiac triggering, so that it is difficult to be quantitatively 
compared in different individuals or in longitudinal studies. Skjold et al. was the 
first to demonstrate quantitative R1 measurements of manganese enhancement by 
Mn-DPDP in myocardial infarction in patients185. Independently, Waghorn et al. 
adapted an ECG-gated, flow-compensated Look-Locker MRI pulse sequence to 
perform R1 mapping of mouse hearts after intravenous infusion of MnCl2 solution 
by applying prospectively a fixed R-R period153. These advances shed lights on 
the potential of manganese-enhanced MRI in in vivo quantitative investigations of 
cardiomyocyte calcium handling and characterization of myocardial pathology. 
 
In 1978, manganese was the first MRI contrast agent being discovered by 
Lauterbur et al186. They demonstrated that the R1 of liver and the heart were the 
most significantly enhanced in major organs after intravenous infusion of 
MnCl2186. In 2010, Hu et al. described a non-linear relationship between the total 
dose of intravenously infused Mn2+ and R1 changes in blood and myocardium, 
using T1 mapping in rats. They further highlighted the importance of investigating 
clearance rates of Mn2+ by liver and kidneys, as well as the influence of cardiac 
function, in order to elucidate the dynamics relating Mn2+ contents in blood, 
myocardium and infusion dose181. It is known that the total change of R1 (∆R1) is 
linearly correlated to the concentration of Mn2+ in blood and myocardium153, 181. 
However, it is not yet well understood how R1 enhancements of myocardium and 
blood are quantitatively determined by the total Mn2+ dose and the rate of Mn2+ 
infusion, despite increasing interests and applications of Mn2+ as a functional 
cardiac MR contrast agent. 
 
To improve the application of quantitative manganese enhanced MRI (MEMRI) 
in in vivo setting and probe dynamic calcium signaling in the heart, several issues 
need to be addressed: 1) A R1 mapping technique with high temporal resolution is 
needed to measure the dynamic changes of Mn2+ influx and efflux in myocardium 
in vivo. 2) What is the inter-relation between i.v. infusion rate/dose and 
blood/myocardium R1 changes in healthy animals? 3) What are the patterns of R1 
enhancement by Mn2+ in animal models of myocardial infarction in vivo? 
 
In this study, firstly a dynamic fast R1 map technique was developed by adapting 
a well-established fast R1 mapping MR sequence187 to achieve a temporal 
resolution of around 1 minute in rats in vivo without breath control. With this 
method, quantitative MEMRI was performed in healthy rats to reveal the 
interrelation between i.v. infusion rate, accumulative MnCl2 (Mn) dose and 
dynamic R1 of arterial blood, liver, skeleton muscle and myocardium. Finally 
quantitative R1 enhancement patterns of MEMRI were characterized in sub-acute 
and chronic myocardial infarct model in rats. 
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4.2 Methods and Materials 
 
MR R1 mapping 
The MRI sequence for R1 mapping was modified from a previously described 
inversion recovery snapshot fast low-angle shot (FLASH) sequence187 by setting a 
prospectively fixed R-R period for cardiac triggering153. Only the first excitation 
pulse was triggered by actual R wave of the heart circle and the rest was by 
prospectively set R-R interval value that was determined immediately before 
starting image acquisition by a home-built cardiac and respiratory monitor. With 2 
to 3 segments, 32 to 40 frames of T1WI were acquired for R1 mapping. The 
imaging parameters were as followed: repetition time 2.5ms, echo time 2ms, flip 
angle (FA) 3°, field of view (FOV) 4cm×4cm, matrix 64×64, slice thickness 2mm 
and average 1. Images were obtained in a short-axis imaging plane of mid-
ventricle. The acquisition time for each R1 map data set was around 1 minute. 
 
Animal preparation 
MEMRI was performed in Lewis rats (male, 200-300g, Charles River, Germany). 
Animals were initially anesthetized by inhalation of oxygen mixed with 4% 
isoflurane (Abbott GmbH, Wiesbaden, Germany) and maintained at 2% isoflurane 
during tail vein catheter procedures. The vein catheter was connected to an 
infusion line controlled by a micro-infusion pump to precisely supply Mn2+ 
contrast agents.  
 
Manganese enhancement schemes in healthy rats 
To investigate the influence of infusion rates of Mn2+ solution on ∆R1 in blood, 
myocardium, liver and skeleton muscle, intravenous administration of Mn2+ 
solution was applied at a low rate of 0.86nmol/min/g (Mn0.86) for 60min in the 
Group Mn0.86 (n=5), and a high rate of 3.3nmol/min/g (Mn3.3) for 30min in the 
Group Mn3.3 (n=4). With the two constant infusion rates and relatively long 
infusion time, ∆R1 in various tissues could be plotted to the function of 
accumulative dose of Mn2+ (converted by infusion rate×infusion time). 
Induction of reperfused MI in rats 
Reperfused MI was induced via anterior sternotomy under isoflurane (Abbott 
GmbH, Wiesbaden, Germany) anesthesia in 5 rats (Wistar, female, 200±30g, 
Charles River, Germany). The left anterior coronary artery was ligated for 
120min, followed by removal of the knot. The animal operation was in 
accordance with the guidelines for research animal care of our institute and 
approved by the local ethic committee.  
 
In vivo MRI acquisition 
After tail vein catheter procedures, the rat was placed in a home-built delivery 
bed. Anesthesia was maintained by inhalation of 1-2% isoflurane mixed in 
oxygen. The physiological body temperature was maintained by a warming pad 
(Winkler GmbH, Germany). In all animals, R1 maps and Cine (FLASH, TE 
1.7ms, frames 12-24) of the same image plane at short axis view of mid-ventricle 
were acquired before (serve as baseline values) and after finishing MnCl2 
enhancement. During the infusion of MnCl2 solution, R1 maps were acquired 
continually to monitor the dynamic changes of R1 in myocardium, arterial blood 
in LV cavity, skeleton muscle and liver. Additionally, R1 maps were acquired 
after the end of MnCl2 infusion: in Group Mn0.86 for 20min and in Group Mn3.3 
for 15min.  
 
To investigate the quantitative Mn2+ uptake in both sub-acute and chronic infarct 
hearts, MEMRI was performed 7 days (n=3) and 68 days (n=3) after MI 
operation. First, baseline R1 was measured at the mid-ventricular plane with the 
same imaging parameters and sequence applied in the Group Mn0.86 and Mn3.3. 
After that, MnCl2 solution was infused via a tail vein catheter controlled by a 
micro-infusion pump, at an infusion rate of 3.3nmol/min/g for 30min. In this 
group R1 maps were acquired during the infusion and 15min after the end of 
infusion.  
 
Isoflurane was adjusted during MnCl2 infusion to achieve stable ratio of heart 
beats/respiration (5-6/1). After in vivo MRI, tail vein catheters were removed and 
animals recovered after isoflurane retrieval. 
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MRI data post-processing and analysis 
By using a custom-written Matlab program, spatially resolved T1 maps were 
calculated pixel-wise based on a monoexponential three parameter least-square fit 
(fitted function was A+Bexp(-TR/T1*)). A linear correction (T1=T1**B/A) 
proposed by Deichmann et al.188 was used to correct apparent relaxation time T1* 
from effects of magnetization saturation coming from the Look-Locker pulse 
train. R1 maps were calculated as the reciprocal of the corrected T1 maps.  
 
The medians of R1 were acquired from the Region of Interest (ROI) of the blood 
pool in the left ventricle (R1blood), myocardium of LV wall (R1myocardium), skeleton 
muscle on the chest wall (R1muscle) and liver (R1liver). The medians of R1 were 
plotted synchronically or to the cumulative doses. The R1 value prior to Mn2+ 
infusion (R1baseline) was calculated based on the median R1 values of each 
considered ROI acquired before MnCl2 infusion. The change of R1 (∆R1) was 
defined as ∆R1=R1-R1baseline. On the plots, data was gridded on a time scale with 
1 minute time interval by using linear interpolation after filtering and smoothing 
when necessary. In each group of animals, the result was expressed as mean±SD 
of the medians of the corresponding time point.  
 
Statistics 
Results were expressed as mean±SD. Significance of difference between variables 
was assessed by student t-test. When p<0.05, the difference was considered 
statistically significant. 
4.3 Results 
 
In vivo fast R1 mapping of myocardium, arterial blood, liver and skeleton 
muscle 
The raw T1WI (for R1 mapping) sets acquired before MnCl2 infusion and at the 
end of MnCl2 enhancement at infusion rates of 0.86nmol/min/g and 
3.3nmol/min/g were presented in Figure 4.1. Representative dynamic R1 maps at 
mid-ventricle short-axis view are shown in Figure 4.2. By using the adapted R1 
mapping MR sequence, the median T1 value of LV myocardium before Mn 
enhancement was 1.451±0.086 second (Sec), comparable to the value acquired by 
ECG triggered, breath controlled and extensively averaged imaging settings in our 
previous studies (1.45±0.009Sec)187 as well as to that measured by a Look-Locker 
sequence with prospectively set R-R period by other groups（1.456±0.173Sec）
153, 181. Before Mn enhancement, the measured T1 values of arterial blood (in left 
ventricle), liver and skeleton muscle (in thorax wall) were 1.779±0.185Sec, 
0.948±0.104Sec and 1.660±0.036Sec, respectively. The baseline T1 of arterial 
blood (T1blood) was similar to the value of a previous study by Hu et al181. Upon 
completion of MnCl2 infusion, significant changes in R1 were observed in 
myocardium, arterial blood, liver and skeleton muscle in both Groups Mn0.86 and 
Mn3.3, as shown in Table 4.1.  
 
Figure 4.1 Raw T1WI of R1 mapping data 
 
Panel-A Raw T1WI of baseline R1 mapping data  
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Panel-B Raw T1WI of R1 mapping data after Mn0.86 infusion for 60 minutes 
(dose=51.6nmol/g) 
 
 
Panel-C Raw T1WI of R1 mapping data after Mn3.3 infusion for 30 minutes 
(dose=99nmol/g) 
 
 
R1 dynamics with i.v. MnCl2 infusion at low infusion rate of 0.86nmol/min/g 
Dynamic R1 changes during Mn0.86 infusion were plotted on Figure 4.4. The 
infusion of Mn at the rate of 0.86nmol/min/g resulted in slightly elevated ∆R1 in 
blood (∆R1blood(L)), reaching the maximum of 0.082±0.097Sec-1 at the end of 
MnCl2 infusion. After Mn infusion finished at 60min, ∆R1blood(L) dropped rapidly 
and followed by a modest rise. Conversely, ∆R1 in myocardium after Mn0.86 
infusion (∆R1myocardium(L)) increased almost linearly during Mn2+ infusion, reached 
its maximum of 0.775±0.241 Sec-1 at the end of infusion and remained almost 
constant in the following 30min. Likewise, ∆R1 in liver after Mn0.86 infusion 
(∆R1liver(L)) rose during Mn2+ infusion but dramatically peaked at the end of 
infusion, followed by rapid decline. In contrast, MnCl2 infusion only caused slight 
elevation of ∆R1 in skeleton muscle (∆R1muscle(L)) at such an infusion rate. 
 
 
Table 4.1 R1 (Sec-1) of various tissues before (baseline) and after MnCl2 enhancement 
 
 
 
Figure 4.2 R1 maps acquired before, during and after Mn0.86 and Mn3.3 infusion. R1 
maps at the infusion rate of Mn0.86: (a) prior to Mn enhancement (baseline), (b) end of 
60min infusion, (c) 20min after the end of infusion. R1 maps at infusion rate of Mn3.3: 
(d) prior to Mn enhancement (baseline), (e) end of 30min infusion, (f) 15min after the end 
of infusion. Mn0.86 infusion for 60min and Mn3.3 infusion for 30min are equivalent to 
51.6nmol/g and 99nmol/g cumulative infusion dose, respectively. 
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R1 dynamics with i.v. MnCl2 infusion at high infusion rate of 3.3nmol/min/g 
Dynamic R1 changes during Mn3.3 infusion were plotted on Figure 4.4. High 
infusion rate of Mn2+ at 3.3nmol/min/g induced significant non-linear increase of 
∆R1myocardium(H). In addition, the slope of the later segment (15-30min) was steeper 
than the early segment (0-15min). Similar to ∆R1blood(L), ∆R1blood(H) peaked at the 
end of Mn infusion and plunged considerably in the first 5min after Mn infusion 
stopped (30-35min). In skeleton muscle, ∆R1muscle(H) was in compliance to 
∆R1blood(H), but with much less extent of enhancement. 
 
 
 
 
Figure 4.3 Plots of R1 dynamics during and after Mn0.86 and Mn3.3 infusion. (a): at 
infusion rate of Mn0.86 (***), R1 plots of blood (blue), myocardium (green), liver (red) 
and muscle (light blue) according to time. (b): at infusion rate of Mn3.3 (ooo), R1 plots of 
blood (blue), myocardium (green), liver (red) and muscle (light blue) according to time.  
 
 
Figure 4.4 Comparison of R1 dynamics induced by Mn0.86 and Mn3.3 infusion. (a): at 
both infusion rates of Mn0.86 (***) and Mn3.3 (ooo), plots of R1 dynamics to infusion 
time in blood (blue), myocardium (green), liver (red) and muscle (light blue). (b): at both 
infusion rates of Mn0.86 (***) and Mn3.3 (ooo), plots of R1 dynamics to cumulative 
infusion dose in blood (blue), myocardium (green), liver (red) and muscle (light blue). 
 
Influence of MnCl2 infusion rate on R1 dynamics at the same dose 
Dynamic R1 changes with low (Mn0.86) and high (Mn3.3) infusion rates were 
plotted to the dose of MnCl2 on Figure 4.4. Given the same total MnCl2 dose, 
MnCl2 infusion rate significantly influenced ∆R1 in various tissues. It has more 
direct and apparent effect on ∆R1blood: at the dose of 51.6nmol/g (equivalent to 60 
minutes infusion of Mn0.86 and 15.6 minutes of Mn3.3), ∆R1blood was about 6 
folds higher (0.8047±0.2014 Sec-1 vs 0.1341±0.0.0458 Sec-1) with the infusion 
rate of 3.3nmol/min/g than with that of 0.86nmol/min/g. At that dose, even though 
less dramatic than ∆R1blood, ∆R1myocardium(L) was lower than ∆R1myocardium(H) by 0.61 
Sec-1. It is demonstrated in Figure 4.5. It seems that MnCl2 concentration in blood 
(indicated by ∆R1blood) directly affected enhancement patterns of ∆R1myocardium: 
when it was very low (∆R1blood(L)), the rate of ∆R1myocardium was almost constant, 
which produced an almost linearly rising curve during Mn2+ infusion; when it was 
high (∆R1blood(H)), the rate of ∆R1myocardium was increasing, which produced a 
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Figure 4.5 Influence of MnCl2 infusion rates on ∆R1 at the same cumulative dose. R1 
maps acquired at the infusion rate of Mn0.86: (a) before Mn infusion (baseline), (b) 
35min after the start of infusion  and (c) 60min after the start of infusion. R1 maps 
acquired at the infusion rate of Mn3.3: (d) before Mn infusion (baseline), (e) 9min after 
the start of infusion and (f) 15min after the start of infusion. (b&e) were acquired at the 
same cumulative dose of MnCl2 at 30nmol/g. (c&f) were acquired at the same cumulative 
infusion dose of MnCl2 at 51.6nmol/g. (g) the plots of ∆R1 in myocardium to the 
cumulative doses. At the same doses, the infusion rate of Mn3.3 resulted in greater 
∆R1myocardium, in comparison to the infusion rate of Mn0.86 (0.61Sec-1 higher at the 
cumulative dose of 51.6nmol/min). 
non-linear curve with increasing slope. In addition, high blood MnCl2 level 
continued to elevate ∆R1myocardium(H) even after stopping high rate MnCl2 infusion. 
In contrast, low blood Mn level after the end of MnCl2 infusion at low rate 
(0.86nmol/min/g) didn’t continue to escalate ∆R1myocardium(L). Similarly, 
∆R1muscle(H) was significantly higher than ∆R1muscle(L) (Figure 4.4).  
 
R1 dynamics in sub-acute and chronic MI rats 
R1 maps and dynamic ∆R1 plots of sub-acute and chronic MI before and after 
Mn3.3 were presented in Figure 4.6 and 4.7, respectively. Blood ∆R1 of sub-acute 
MI on Day 7 (∆R1blood(MI_D7)) was significantly reduced to almost half of that in 
non-infarcted rats (control, Mn3.3). In contrast, blood ∆R1 of chronic MI rats on 
Day 68 (∆R1blood(MI_D68)) was similar to that of the control (Figure 4.7, Panel-A). 
In MI zones, ∆R1 on Day 7 (∆R1MI(MI_D7))  was significantly lower than 
∆R1myocardium in non-infarcted rats with Mn3.3 (∆R1myocardium(H)) and ∆R1 of 
remote non-infarcted myocardium of infarct rats (∆R1Remote(MI_D7)). On Day 68, 
∆R1 of MI segments (∆R1MI(MI_D68)) increased significantly. However, the ∆R1 
enhancement of MI zone was mainly induced by the composition of blood volume 
with increased ∆R1blood and a small fraction of Mn2+ that permeated to 
extravasculature.   In contrast, the non-infarcted Group Mn3.3 showed continuous 
fast increase of ∆R1myocardium during Mn2+ infusion and followed by slight rise in 
the subsequent 15min (Figure 4.7, Panel-B). 7 days after MI, the remote non-
infarcted myocardium demonstrated almost 50% attenuated ∆R1 enhancement 
(∆R1remote(MI_D7)) during Mn3.3 infusion, in comparison to the control on the same 
day. But it differed from ∆R1 of the infarcted segments in sub-acute phase (Day 
7) by much faster R1 increase beyond ∆R1blood(MI_D7) during Mn infusion (Figure 
4.7, Panel-C). ∆R1 of peripheral MI areas (∆R1periMI(MI_D7)) and ∆R1remote(MI_D7) 
shared similar characteristics in enhancement patterns (Figure 4.7, Panel-D). 
Notably, both ∆R1periMI(MI_D68)  and ∆R1remote(MI_D68) were much recovered, even 
though still slightly below that of the control. In sub-acute and chronic MI, 
differential patterns of ∆R1 dynamics appeared in the remote non-infarcted 
myocardium, 15min after the end of Mn3.3 infusion. In sub-acute MI, 
∆R1remote(MI_D7) declined fast after the end of Mn infusion. In contrast, 
∆R1remote(MI_D68) mostly remained constant during this period, similarly to that of 
non-infarcted rats.  
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Figure 4.6 R1 maps on Day 7 and Day 68 of the same MI heart of rat with Mn3.3 
infusion. On Day 7 post-MI, R1 maps were acquired: (a) before the start of Mn infusion 
(baseline), (b) at the end of 30min infusion and (c) 15min after the end of infusion. On 
Day 68 after MI, R1 maps were acquired again in the same animal: (d) before the start of 
Mn infusion (baseline), at the end of 30min Mn infusion and (f) 15min after the end of 
Mn infusion. 
 
 
In addition, the ∆R1 plots of individual animal could provide specific information 
concerning MI characteristics. As on Figure 4.7, Panel-E shows the mean ∆R1MI 
plot of the whole group of chronic infarct rats (Day 68 post-MI), together with the 
individual ∆R1MI plots of each animal in this group. The ∆R1MI enhancement 
patterns of the three individuals in the group were similar during the infusion of 
Mn3.3, well-presented by the group mean plots. However, one of the individual 
exhibited sustained ∆R1MI after the end of Mn3.3 infusion, which likely indicates 
significant amount of viable myocardium in the MI zone. The ∆R1MI plots of the 
other two animals showed high compliance to ∆R1blood, which suggests a lack of 
viable myocardium. However, this difference was not well presented by the group 
mean ∆R1MI plots. 
  
 
 
Figure 4.7 Dynamic ∆R1 measurements of MI rats with Mn3.3 infusion.  
 
 
 
 
 
 
 
 
 
 
 
 
Panel-A ∆R1blood (mean±SD) plots of MI and control rats on Days 7 and 68 after 
infarction. ∆R1blood of MI rats on Day 7 (red curve) was significantly lower than ∆R1blood 
of  control rats (green curve) or MI rats on Day 68 (blue curve). 
  
 
Panel-B ∆R1MI (mean±SD) plots of MI rats on Days 7 and 68 after infarction, as well as 
the relation between ∆R1MI and ∆R1blood. ∆R1MI on Days 7 and 68 post-MI were similar to 
their corresponding ∆R1blood. ∆R1MI on Day 7 was lower than that on Day 68 post-
infarction. 
 
 Panel-C ∆R1periMI (mean±SD) plots of MI rats on Days 7 and 68 after infarction, as well 
as the relation between ∆R1periMI and ∆R1blood. ∆R1periMI on Day 68 appeared similar to 
∆R1myocardium of control rats. However, ∆R1periMI  on Day 7 was much lower than that on 
Day 68, probably due to the decreased ∆R1blood. 
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Panel-D ∆R1remote (mean±SD) plots of MI rats on Days 7 and 68 after infarction, as well 
as the relation between ∆R1remote and ∆R1blood. ∆R1remote on Day 68 appeared similar to 
∆R1myocardium of control rats. However, ∆R1remote on Day 7 is lower than that on Day 68, 
probably due to the decreased ∆R1blood.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel-E Plots of ∆R1MI on Day 68 post-MI. Red curves: ∆R1MI of individual animals. 
Blue curve: ∆R1MI of the group mean±SD. Large variations of ∆R1MI were seen among 
the individual animals, especially after the end of Mn3.3 infusion. The two red curves 
with fast decline of ∆R1MI, after the end of Mn infusion, probably suggest transmural MI 
with very few viable myocardium. The red curve with sustained ∆R1MI after the end of 
Mn infusion was probably a non-transmural MI containing significant amount of viable 
myocardium. 
4.4 Discussion 
 
The adapted fast R1 mapping method in this study was able to simultaneously 
measure dynamic R1 changes in myocardium, blood, skeleton muscle and liver in 
vivo, with a temporal resolution of around 1 minute. Waghorn et al. were among 
the first to apply R1 maps to quantitatively study Mn enhancement in myocardium 
in vivo at high field MRI153. They also suggested that their method has potential to 
quantitatively investigate calcium signaling in myocardium in vivo. However, the 
long acquisition time of 45min for one R1 map largely limited their method to 
achieve precise and dynamic results in vivo, because the concentration of 
intracellular Mn2+ gradually decreases after the cease of MnCl2 infusion. They 
showed almost 80% reduction of R1 in myocardium 3-4 hours after infusion. 
Therefore, the decline of R1 in myocardium is expected to be significant during 
the 45-minute acquisition of R1 map. On the other hand, such a long image 
acquisition time does not allow monitoring of fast dynamic changes of R1 in 
myocardium and other tissues or organs (e.g. blood, liver), which are critical in 
understanding the in vivo kinetics of MnCl2180. In addition, the observation of 
modulated calcium influx by inotropic agents or pathophysiology demands rapid 
measurements of R1. Our dynamic R1 mapping method with high temporal and 
spatial resolution sensitively detected a wide range of R1 changes caused by 
MnCl2 infusion, which has gained new insights concerning the interrelations 
between MnCl2 infusion rates/doses and ∆R1 in various tissues. In addition, 
differences in MnCl2 kinetics and R1 enhancement patterns were observed 
between sub-acute and chronic MI rats in vivo. These findings might be valuable 
for 1) better understanding of the complex kinetics of Mn2+ contrast agent in vivo, 
2) realizing the potential of Mn2+ contrast agents for quantitative studies of 
calcium signaling in vivo and 3) the clinical translation of MEMRI in the future.  
 
Infusion rates of Mn2+ directly influenced concentrations of Mn2+ in blood 
The constant i.v. infusion rate resulted in increasing concentrations of blood Mn2+ 
and accumulative doses with time. It is known that the clearance of free Mn2+ 
from plasma is a fast multi-component process with half-life times shorter than 1-
2 minutes189-191.  After intravenous injection, a majority of Mn2+ ions quickly bind 
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to plasma macromolecules. The rest of the free Mn2+ has a kinetics that is largely 
unknown. A higher infusion rate of Mn2+ resulted in higher concentrations of both 
the free and bound Mn2+ in blood, even though it is unclear what is the exact ratio 
between the two in blood. Our results indicated that there was more ‘in’ (i.v. 
infusion) than ‘out’ (clearance from circulation) of Mn2+ in blood during infusions 
of Mn0.86 and Mn3.3, resulting in gradual rise of Mn2+ concentration in blood. 
This accumulation of Mn2+ in blood impacted the R1 enhancement patterns in 
both myocardium and skeleton muscle.  In the former, the rate of ∆R1myocardium 
increased with time during Mn2+ infusion, most likely due to the increased supply 
of free Mn2+ for active uptake by cardiac myocytes. In contrast, relaxed skeleton 
muscle didn’t take up Mn2+ actively due to the lack of excitement. Its ∆R1 was 
mostly contributed by the elevated ∆R1 of blood in tissue. Therefore, the 
increasing concentration of Mn2+ in blood during infusion needs to be considered, 
especially when quantitative dynamic observation is desired for measuring tissue 
activity e.g. quantitative calcium influx in myocardium, by applying a constant 
rate of Mn2+ infusion. It seems that a lower infusion rate of Mn2+ is more likely to 
deliver a close-constant supply of free Mn2+ in blood. 
 
Infusion rates of Mn2+ significantly affected R1 enhancement patterns of 
myocardium 
Infusion rates of Mn2+ significantly influenced total concentration of Mn2+ in 
arterial blood as well as the relationship between MnCl2 doses and ∆R1 of various 
tissues.  ∆R1blood(H) was much higher than ∆R1blood(L), given the same total dose of 
Mn. Moreover, a low infusion rate of Mn (0.86nmol/min/g) delivered close-linear 
increase of ∆R1myocardium(L), in the dose range of 0-51.6nmol/g. However, in the 
same dose range, a high infusion rate of Mn (3.3nmol/min/g) produced greater 
∆R1myocardium with faster increase (steeper slop on ∆R1 plots). For example, the 
mean ∆R1myocardium(H) was 0.61Sec-1 greater than the mean ∆R1myocardium(L) at the 
dose of 51.6nmol/g. It is also noted that ∆Rblood(H) was around 0.67 Sec-1 higher 
than ∆Rblood(L). As estimated, the blood volume fraction (with ∆Rblood(H)) in 
myocardium could only contribute around 0.2 Sec-1 or less to the ∆Rmyocardium(H) at 
such dose, when the blood volume fraction of myocardium is 10-15%. Therefore, 
the significantly higher ∆Rmyocardium(H) should be a result of substantially more 
uptake of Mn2+ in cardiomyocytes. The significantly greater ∆R1myocardium(H) at the 
MnCl2 dose of 51.6nmol/g projects an even larger difference at higher doses of 
MnCl2 infusion. It seems that a higher infusion rate of Mn2+ is more efficient for 
R1 enhancement of myocardium, given the same cumulative dose. 
 
Unexpected reduction of ∆R1blood in sub-acute MI rats  
The significantly reduced ∆R1blood in sub-acute MI rats (Day 7) was surprising. 
Assuming the clearance of MnCl2 is considerably influenced by hemodynamics 
and heart function, it is still difficult to explain the large difference between 
∆R1blood in sub-acute (Day 7) and chronic (Day 68) MI rats, since the ejection 
fraction is normally only a few percentage difference between sub-acute and 
chronic MI. In addition, ∆R1blood of chronic MI rats was similar to that of non-
infarcted animals. Nevertheless, this finding highlights the importance of relating 
∆R1myocardium to the corresponding ∆R1blood, in order to avoid mis-interpretation of  
quantitative R1 enhancement in myocardium. 
 
In addition, it seems that the Ca2+ efflux was modulated in the remote non-
infarcted myocardium during sub-acute MI phase, based on the observation of the 
rapid decrease of R1 after Mn3.3 infusion (30-45min) on Day 7. This could not be 
easily explained by the lower R1blood in MI rats on Day 7, because no obvious 
reduction on R1myocardium(L) was seem after Mn0.86 infusion (60-90min) in the 
Group Mn0.86. The significance of this phenomenon is to be determined.  
 
∆R1myocardium is closely related to ∆R1blood and other factors 
Mn2+ enhancement in myocardium is mainly determined by 1) the capability of 
active uptake of Mn2+ into cardiomyocytes by L-type calcium channels, 2) the 
permeability of cell membrane to allow for efflux of Mn2+, 3) the concentration of 
Mn2+ in perfusion blood and 4) the arterial perfusion of myocardium. To 
investigate 1) and 2), the concentration of Mn2+ in blood and arterial perfusion 
needs to be controlled. In sub-acute MI (Day 7) rats, the significantly reduced 
R1blood suggested a lower Mn2+ concentration in blood. Associating with changes 
in regional and global contractility, LV remodeling also occurs in 
microvasculature and perfusion in remote non-infarcted myocardium. Therefore,  
it is critical to relate ∆R1myocardium to ∆R1blood and myocardial arterial perfusion, 
when MEMRI is interpreted quantitatively to extract biological meanings.
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4.5 Conclusions 
 
We improved the quantitative manganese enhanced MRI method and applied it in 
both sub-acute and chronic MI rats, to probe the influx and efflux of calcium ions 
in infarcted and non-infarcted myocardium in vivo. We revealed that intravenous 
infusion rates of manganese significantly influenced the change of R1 in blood 
and therefore that of R1 in myocardium, given the same total infusion dose. 
Interestingly, significantly reduced R1 enhancement was observed in various 
tissues in sub-acute MI rats, in comparison to both control and chronic MI rats. 
This phenomenon seems largely, if not entirely, due to the significantly reduced 
manganese ion concentration in arterial blood in sub-acute MI rats. These findings 
highlight the importance of relating R1 enhancement in myocardium to the 
changes of R1 in blood and myocardial arterial perfusion, when interpreting 
quantitative MEMRI as a surrogate of calcium activities in myocardium.  
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